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ABSTRACT
This study was designed to evaluate the neuropsychopharmacological profile of Kalyanakam 
Kashayam, an Ayurvedic formulation in various experimental models. The formulation was 
evaluated for its anti-depressant activity using Pentobarbitone – induced sleeping time, 
Actophotometer test and Forced swim test. It was found out that the formulation produced 
significant potentiation of sleeping time induced by pentobarbitone, mild reduction in immobility 
time in forced swim test and significant increase in locomotor activity. Anxiolytic activity was 
assessed using the Elevated plus maze model and Hole board test. The formulation significantly
increased the time spent by the animal in open arm without affecting the number of entries to 
both the arms in elevated plus maze model and a promising reduction in the number of nose 
poking in hole board test. The results of the study provided evidences that Kalyanakam 
Kashayama is a promising antidepressant, anxiolytic and antipsychotic agent. The formulation
showed no significant effect on fall off time in Rotarod test which indicated the Non –
neurotoxic behavior of the Formulation. In Haloperidol – induced catalepsy model, a significant 
reduction in cataleptic time was observed. The current study also recommended that the 
formulation is an impending atypical antipsychotic agent against schizophrenia using 
Apomorphine–induced stereotypy model and an effective anti-convulsant drug in 
Pentylenetetrazol – induced convulsion models.
Key words:  Kalyanakam kashayam; Formulation; mice; Neuropsychopharmacological profile.
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1. INTRODUCTION
Neuropsychopharmacology
Neuropsychopharmacology may be defined as the branch of inter 
disciplinary neuroscience devoted to the study of drugs that have an effect on the nervous tissue 
and alter the behavior. Neuropharmacology deals with the study of effects of the drug on nerve 
cells, their synapses and circuit whereas the study of effects of drugs on behaviors, including 
emotional and cognitive mental activities, is Psychopharmacology. It associates the frontiers of 
fundamental neuroscience to the management of psychiatric and neurological diseases. This 
branch of science seeks to comprehend how drugs selectively affect the CNS to induce sleep, 
relieve pain, reduce fever, suppress muddled movement, prevent seizures or enhance attention. 
Neuropsychopharmacology seeks to understand how drugs can treat mania, anxiety, 
schizophrenia or depression without disturbing the consciousness. This field seeks to uncover the 
biological basis for intricate mental states. The goal of this field is not only to understand the 
nature of the alterations in biology which direct to distorted emotions and thought processes, but 
also to develop therapeutically priceless specific molecules which regulate the specific biologic 
underpinnings- namely, the as yet vague sequences of multineuronal interactions by which the 
behaviors emerge [1].
Advance in modern science and technology have contributed to an enormous 
development in the quality of human life. However, modern life stresses are responsible for the 
surge in incidence of variety of psychiatric disorder. Drugs that are currently used in managing 
different neuropsychiatric and neurological disorders like anxiety, depression, schizophrenia, 
epilepsy, Parkinsonism either  have severe side effects or posses inauspicious drug-drug/drug-
food interactions. Moreover, the western system of medicine pays no heed to the fundamental 
problems and depends on drug treatment to cure the symptoms. The western restorative 
treatment fails to tackle the huge diversity among patients. In this context, Ayurvedic treatment, 
which considers a patient’s entire body-mind-spirit relationship and bioindividuality which aims 
to look at the root cause of the disease and it’s relation with the lifestyle, thoughts and beliefs of 
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the person (vital energy of the patient), have attained widespread fame in treating the neurologic 
disorders than the western system of medicine [2].
Ayurveda (Ayur = life, Veda = Knowledge) is concerned about the absolute 
wellness together with, psychological, physical, social wellness, economical as well as spiritual 
security. The prime goal of Ayurvedic medication is to facilitate people live long hence known 
as the science of longetivity), hale and hearty and balanced lives with no need for problematical 
surgery, chemical drugs or tormented through painful conditions. The basic principle of 
Ayurveda is the belief that distress and ailment results from disparity in three doshas (Vata, Pitta 
and Kapha) which are the three basic energy types of the body. These doshas are the prime 
determinants of body type, energy levels, appetite, tendencies and moods and are considered and 
checked by the physicians to prescribe the essential medication. The major aspects of Ayurvedic 
restoration of balance includes tuning of the natural rhythms of our body and also synchronizing 
our body with nature and its cyclic patterns which helps to relieve stress and also restore the 
circadian rhythm of our body.
The Indian subcontinent is an immense warehouse of curative plants that 
are used in customary medical healing. The unconventional medicines in the deep-rooted system 
are derivatives of herbs, organic matter and minerals, whilst for the preparation of herbal drugs 
only medicinal plants are used. Utilization of plants as a foundation of medicine has been a 
primordial practice and is a significant component of the Indian health care system. In India, 
approximately 70 percentage of rustic population depends upon the customary Ayurvedic 
scheme of medicine. Most practitioners/ healers of the conventional system of medication 
prepare formulations by their individual recipes and dole out to the patients. About 40% of 
people in the Western countries make use of the herbal medication for the management of a 
variety of diseases. This concern in traditional remedy is budding swiftly due to the concern 
being given to it by the governmental organization and various NGO’s encompassing researchers 
and common public as well as the amplified adverse drug reactions, side effects and cost of the 
recent drugs.
In India, about 20,000 curative plants have been documented; 
nevertheless, time-honored practitioners make use of only 7,000–7,500 plants for treating diverse 
diseases. The ratio of use of plants in various Indian systems of remedy is Ayurveda-2000, 
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Siddha-1300, Unani-1000, Homeopathy-800, Tibetan-500, current-200, and folk 4500. Roughly 
25,000 valuable plant-based formulations are made use of in conventional and folk medication. 
Over 1.5 million practitioners are using the long-established therapeutic scheme for wellbeing in 
India. It is anticipated that over 7800 manufacturing units are concerned with the formulation of 
natural health products and conventional plant-based formulations in India, which makes use of 
approximately 2000 tons of medicinal crude plant material per annum. About1500 herbals are 
vended as nutritional add-on or ethnic conventional medicines. Alternative medications are being 
used by people who cannot be facilitated by traditional medicinal scheme.
The breakthrough of herbals is additionally harmonized with acquaintance 
on the technique of seclusion, purification, portrayal of active components and category of 
preparation. The phrase “herbal drug” resolve the fraction/fractions of a plant (flowers, leaves, 
seeds, barks, roots and stems etc.) used for preparing medication. Each and every fraction of the 
herbs are entirely made use of for the dissimilar pharmacological action they probably will 
engender and refined into an array of herbal preparations together with Phanta (Hot infusion),
Kwatha (Decoction), Hima(Cold infusion), Guggul (Resins and balsams), Churna (Powders),
Arka (Liquid Extract), Taila (Medicated oil) and etc.
Owing to the technical or scientific encroachment today, auxiliary 
pharmacologically dynamic ingredients of the Ayurvedic medication with their utility in drug 
treatment have been recognized. Fundamentally, it is the phytochemical component in the herbs 
which direct to the preferred therapeutic effect, such as tannins, saponins, alkaloids, flavonoids, 
alkenyl phenols, terpenoids, sesquiterpenes lactones and phorbol esters. A solitary herb may yet 
contain more than one of the aforesaid phytochemical ingredients, which acts synergistically 
with each other in fabricating pharmacological action.
Single herbals and Polyherbal formulation
Ayurvedic drug formulation is based on two ideologies; Utilized as a sole 
drug and use of more than single drugs, in which the latter is known as Polyherbal Formulation 
(PHF). This key conventional curative herbal approach takes advantage of combining of 
numerous therapeutic herbs to accomplish additional therapeutic efficacy, typically known as 
polyherbalism or polypharmacy.
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In times gone by, the Ayurvedic prose “Sarangdhar Samhita” dated 
centuries in the past in 1300 A. D. has highlighted the perception of polyherbalism in this 
prehistoric curative system. In the traditional system of Indian medicine, plant formulations and 
combined extracts of plants are chosen rather than individual ones. Ayurvedic herbals are 
prepared in various types of dosage forms, in which typically almost all of them are PHF.
Even though the dynamic phytochemical components of each plant have 
been well recognized, they more often than not present in infinitesimal amount and constantly, 
they are inadequate to accomplish the enviable therapeutic effects. For this, methodical or 
scientific studies have exposed that these flora of changeable effectiveness when united may 
tentatively fabricate a superior result, as weighed against individual use of the herbals and also 
the totting up of their individual outcome. This trend of constructive herb-herb interaction is 
recognized as synergism. Some of the pharmacological actions of dynamic elements of herbals 
are noteworthy only when potentiated by that of supplementary plants, but not apparent when 
used alone.
Depending upon the nature of the interaction, synergism acts by two 
mechanisms (i.e., pharmacokinetic and pharmacodynamics). The capacity of herb to facilitate the 
absorption, distribution, metabolism and elimination of the additional herbs are focused in 
pharmacokinetic synergism. On the other hand, Pharmacodynamic synergism deals with the 
synergistic outcome when dynamic ingredients with alike remedial activity are embattled to a 
analogous receptor or physiological system. As a result of synergism, polyherbalism bestow 
some reimbursement not accessible in sole herbal formulation. It is apparent that superior 
restorative result can be arrived at with a solo multi-component formulation. In favor of this, an 
inferior dose of the herbal formulation would be desired to accomplish enviable pharmacological 
action, thus tumbling the peril of lethal side-effects. Moreover, PHFs fetch to enhanced 
expediency for patients by eradicating the need of taking additional different single herbal 
formulation at an instance, which ultimately guide to improved acquiescence and restorative 
effect. When weighed against single herbal formulations, all these reimbursement have paved 
way to the popularity of PHF in the market.
During the formulation of polyherbal preparations, it is decisive to note 
down that herbs are every so often considered to be unable to coexist (viruddha) and thus ought 
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not to be taken in concert. Such incongruity may be owing to quantitative inaptness, functional 
incompatibility or energetic incompatibility. To guarantee compatibility of manifold herbs in the 
PHF formulation, there is a need of ingenious clinical trials preceding marketing.
Reasons for using PHF
It is well-known that PHF have started to achieve its fame recently globally, due 
to the verity that PHFs own some advantages which is inaccessible in allopathic drugs.
At the outset, PHFs are recognized to articulate sky-scraping efficacy in an 
enormous number of ailments. As aforesaid, the remedial effects of herbal medications are put 
forth due to the incidence of dissimilar phytoconstituents and the effects are additionally 
potentiated when well-matched herbals are put together in PHFs.
Secondly, PHFs are typically established to have extensive therapeutic 
assortment. Majority of them are efficient even at a very low dose and safe and sound at elevated 
dose, thus they include better peril to assistance ratio.
Commonly, PHFs (restricted to those properly used manufactured) result 
in smaller number of side effects as weighed against allopathic drugs. While contemporary 
allopathic drugs are intended for effectual restorative results, management of majority of them 
come up with unnecessary side-effects, such as vomiting, insomnia, fatigue, diarrhea, dry mouth,  
seizures, confusion, impotency, organ toxicities, hair loss and even demise. 
Due to the verity that PHFs are a product of the nature, they are 
comparatively cheaper, biodegradable and readily accessible than allopathic drugs. Their better
affordability and greater accessibility explains the ever-increasing demand worldwide, chiefly in 
rustic areas and some developing countries, where expensive contemporary treatments are 
inaccessible. Furthermore, right through the history, polyherbal cure have long stand as 
conventional attitudes, customs and practices in certain ethnic group, which are based upon 
centuries old knowledge of tryout and slip-up. 
All the above mentioned motives: Effectiveness, cheap, safety, better 
acceptance and ubiquity, made PHF the ultimate choice of treatment, for this reason superior 
acquiescence by the patients and exceptional curative effect is made certain.
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Major problems related to PHF usage
Regardless of the verity that Ayurvedic PHFs are valuable to mankind in 
loads of facet, they are still disputed by some inevitable shortcomings, upsetting their capability 
and effectiveness in cure. These troubles lie within the PHFs’ resource and manufacturing 
procedure, Ayurvedic practitioners, patients, as well as the regulations and law.
There is a sturdy fallacy that Ayurvedic PHFs are constantly safe, which is 
fictitious. Charaka Samhita itself has depicted that Ayurvedic medications have unpleasant 
effects when used or prepared improperly. The concomitant use of allopathic drugs with PHFs is 
growing as a good number of the individual patients do not notify their medical practitioners on 
the parallel treatments. Nevertheless, countless have not noted the probable drug-herb 
interactions, which may have an effect on their pharmacological or toxicological effects, 
consequently results in unpleasant effects that depreciate wellbeing [3].
Herbalists consider that it is significant to confer not merely the 
“hardware” of the brain and nervous system, but its “software,” the emotions and mind as well. 
Every single one of these chemical responses and reactions are indispensable to our indulgent of 
the nervous system, and focusing on neurotransmitters and hormones can undoubtedly bid us 
insight into psychological processes [4]. Mental factors apparently are concerned in nervous 
system wellbeing. Current proceedings in the field of neurology have come about through the 
assessment of allege for herbal medications. Majority of the quarter of apprehension of 
neurology will potentially get assistance from herbal remedies, and undeniably the discipline of 
psycho-pharmacology itself is principally based upon the chemicals discovered in plants [5].
In the Ayurvedic system of medication, for CNS disorders polyherbal 
formulations are recurrently prescribed and the plant constituent in these formulations augment 
the activity of compounds or neutralize the noxious effect of compounds from other plants but 
also work synergistically with additional constituents from the same plants. Till date no research 
work has been carried out on the formulation. For that reason, it was considered valuable to 
investigate neuropharmacological effects of Kalyanakam kashayam to corroborate the claim 
made by conventional healers as well as in Ayurveda.
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Thus the prime concern of the study is to evaluate the nootropic activity of 
the selected Ayurvedic Polyherbal Formulation “Kalyanakam Kashayam” in various animal 
models. 
Neurotransmission
Neurotransmission may be defined as the process of transfer of impulses 
between neurons and Neurotransmitters are those biochemical substances responsible for the 
transmission of nerve signals across a synapse between two neurons.
The Central Nervous System uses a wide variety of Neurotransmitters 
including both Excitatory and Inhibitory chemical transmitters including:
1. Biogenic Amines
∑ Dopamine
∑ Norepinephrine
∑ Epinephrine
∑ Serotonine
∑ Histamine
2. Amino Acids
∑ Glutamic Acid
∑ Aspartic Acid
∑ Gama Amino Butyric Acid
∑ Glycine
3. Peptides
∑ Angiotensin
∑ Endorphins
∑ Vasopressin
∑ Substance P etc.
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4. Others 
∑ Purines (Adenosine & Adenosine Triphosphate)
∑ Nitric Oxide
Acetylcholine and Monoamines are ought to perform specialized 
regulating functions, often limited to explicit structures. The peptides regulate neuronal function 
by themselves or in concert with other neurotransmitters and execute specialized functions 
mainly in hypothalamus.
Table-1: Some Neurotransmitters found in Nervous system
Name Effects Receptor 
subtype
Receptor motif Mechanism
AMINES
Acetylcholine
Norepinephrine
Dopamine 
Serotonin (5HT)
Both excitatory 
& inhibitory
Both excitation 
& inhibition in 
the brain stem
Predominantly 
Inhibitory
Both excitatory 
& inhibitory
Mainly 
Nicotinic
Muscarinic
α1
α2
β1 , β2, β3
D1, D5
D2, D3, D4 
5HT1
5HT2
5HT3
Ionotropic
Metabotropic
Metabotropic
Metabotropic
Metabotropic
Metabotropic
Metabotropic
Metabotropic
Metabotropic
Ionotropic
Na+, K+,Ca2+ conductance
IP3/DAG/Ca
2+
cAMP,    K+ conductance
IP3/DAG/Ca
2+
cAMP,  K+,Ca2+conductance
cAMP
cAMP
cAMP,  K+, Ca2+conductance
cAMP,    K+ conductance
IP3/DAG/Ca
2+
Na+, K+,Ca2+ conductance
cAMP
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Histamine 
inhibitory.
Functions 
uncertain.
5HT4-7
H1
H2
H3
Metabotropic
Metabotropic
Metabotropic
Unknown 
IP3/DAG/Ca
2+
cAMP
Unknown
Amino Acids
Glycine 
Glutamate &
Aspartate 
Gama-
aminobutyric acid 
(GABA)
Inhibitory
Excitatory 
Inhibitory
α ,β subunits 
AMPA
Kainate 
NMDA
mGlu(1-7)
GABAA
GABAB
Ionotropic
Ionotropic
Ionotropic
Ionotropic
Metabotropic
Ionotropic
Metabotropic
Cl- conductance
Na+, K+ conductance
Na+, K+ conductance
Na+, K+,Ca2+ conductance
cAMP
IP3/DAG/Ca
2+
cAMP
Cl- , K+ conductance
MAJOR NEUROLOGIC DISORDERS
Human beings accomplish competence through multifaceted integrated 
processes. The major neural system which account for this competence includes; sensory, motor 
and cognition systems. Alteration in all of this or any one of them has an effect on competence. 
Some of the disorders associated with disturbances in the activity of neurological system include:
Introduction 
Department of Pharmacology Page 10
∑ Parkinson’s disease
∑ Alzheimer’s disease
∑ Anxiety
∑ Depression
∑ Schizophrenia [6] [7] [8]
PARKINSON’S DISEASE
It is a neurodegenerative disorder of corpus striatum (basal ganglia) 
involving the dopamine-secreting nigrosriatal pathway. There is a profound loss of dopaminergic 
neuron (atleast 70%) when the first symptoms appear. The onset of the ailment occurs following 
40 years of age. Men are more prone to the disease than women. It is one of the most prevalent 
neurological disorders in individuals older than 60 years. Approximately 107 to 187 per 100,000 
persons are affected by the disorder.
Etiologic classification
Primary Parkinson’s disease- Loss of pigmented neurons in the substantia nigra, chiefly in the 
medial and ventral segment allied with reactive gliosis.  
Secondary Parkinson’s disease- Caused by disorders like infection, trauma, neoplasm, toxins, 
atherosclerosis, drug intoxication etc. Drugs like neuroleptics, anti-hypertensives, anti-emetics 
etc are the common cause of drug induced Parkinsonism. 1-methyl-4-phenyl- 1, 2, 3, 6-
Tetrahydropyridine (MPTP) produces a Parkinsonian syndrome due to the degeneration of locus 
ceruleus and substatia nigra, in users.
Pathophysiology
The pathogenesis of the disease is not evidently known. Studies illustrate 
that there is an autosomal dominant form involving mutation in alpha synuclein gene on 
Chromosome 4 (4q21.23) and an autosomal recessive form (ARDP) involving mutation in the 
parkin gene on Chromosome 6 (6q 25.2-27).
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Pathologic feature: 
Dopaminergic nigrostrial pathway composed of ‘Black substance’ 
(neurons of substantia nigra) with the fibres synapsing in the caudate and putamen basal ganglia. 
Exhaustion of dopamine in substatia nigra and basal ganglia is the prime biochemical alteration 
in Parkinsonism. In the disease, depletion of dopamine in the basal ganglia and a comparative 
excess of cholinergic activity in feedback circuit linking basal ganglia, thalamus and cerebral 
cortex, occurs as a result of nigrostraital dopaminergic pathway. Age influences nigrostriatal by 
environmental toxins. MPTP (chemical neurotoxin) have the capacity to selectively destruct the 
cells of substantia nigra and and can produce irreversible Parkinsonian syndrome. 
Clinical Manifestations 
∑ Resting tremor involving ‘pill-rolling’ movements of the hand.  
∑ Slow initiation of movements (Bradykinesia)
∑ Abnormal posture
∑ Muscular rigidity
∑ A blank facial expression
∑ A characteristic shuffling gait
∑ Inability to perform skilled tasks.
∑ Speech impairment. 
Drug therapy
The drug therapy for Parkinson’s disease includes:
1. Drugs increasing Dopaminergic activity
∑ Precursors of Dopamine: Levodopa
∑ Inhibitors of Dopamine metabolism:
v COMT inhibitors: Tolcapone, entacapone
v MAO-B inhibitors: Selegiline,rasagiline
∑ Dopamine releasers: Amantadine
∑ Dopamine receptor agonists:
Introduction 
Department of Pharmacology Page 12
v Ergot derivatives: Bromocriptine, Pramipexole, Ropinirole
v Non-Ergor derivatives: Lysuride
2. Drugs that affect brain cholinergic system
v Central anti-cholinergic drugs: Procyclidine, benzhexol
v Antihistaminics: Promethazine, orphenadrine [9] 10] [11] [12] [13].
SCHIZOPHRENIA
Schizophrenia may be defined as a thought disorder typified by one or 
more episodes of psychosis i.e. impairment in reality testing. Individuals in their late teens and 
early 20’s are affected by schizophrenia. Schizophrenia is ought to have a multifactorial etiology, 
involving both environmental and genetic components.
Pathogenesis
The pathogenesis of schizophrenia is best explained by the Dopamine 
hypothesis. The hypothesis states the disorder is caused as a result of the deregulated and 
increased brain Dopamine levels. The deregulation is proposed to occur at meticulous anatomic 
locations in brain. Mesolimbic system is such a system which is believed to be the root cause of 
the positive symptoms of schizophrenia (due to hyperactivity of the system), whereas the 
dysfunction of alterations in the Mesocortical system is responsible for the negative symptoms of 
the disease. 
The dopamine hypothesis is supported by fact that some D2 antagonistic 
drugs relieves the symptoms of the disorder, while CNS dopamine receptor activators like 
cocaine, apomorphine etc worsens the disorder which is subsided when the dose of the drugs are 
reduced.  
It was also observed that, Schizophrenia like symptoms are aggravated in 
some patients taking phencyclidine (NMDA receptor antagonist) which suggests the role of 
imbalance in glutamate neurotransmission in schizophrenia. 
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Symptoms:
1. Positive symptoms
∑ Hallucinations
Visual 
Auditory
Somatic- tactile
∑ Delusions 
Delusions of mind reading
Delusions of being controlled
Delusions of reference
Persecutory
∑ Positive formal thought disorder
Derailment
∑ Bizarre behavior
Stereotyped, repetitive
Agitated, aggressive
2. Negative symptoms
∑ Affective flattening 
Decreased spontaneous movements
Affective non responsivity
Lack of vocal inflections
∑ Alogia
Poverty of speech
Blocking
∑ Anhedonia – associality
Few social relationships
Few recreational interests 
∑ Attention
Inattentiveness during testing
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Social inattentiveness
∑ Avolition – apathy
Lack of persistence
Physical anergia 
Drug therapy:
Antipsychotic drugs
∑ Phenothiazines: Chlorpromazine
∑ Rauwolfia alkaloids: Reserpine
∑ Butyrophenones: Haloperidol
∑ Diphenylbutylpiperidines: Pimozide
∑ Thioxanthenes: Flupentixol
∑ Indole derivates: Molindone
∑ Dibenzodiazepines: Clozapines
∑ Substituted benzamides: Sulpiride
∑ Miscellaneous: Olanzapine [14] [15] [16].
ALZHEIMER’S DISEASE
It is a common neurologic disorder which is also known as senile disease 
complex or dementia of Alzheimer’s type. It is a common disease of elderly people and is found 
to be the major severe cognitive dysfunction. The major risk factor of the disease is age. The 
prevalent forms of the disease are:
∑ Early-onset familial dementia
∑ Late-onset familial Alzheimer’s disease (FAD)
∑ Sporadic or nonhereditary late onset Alzheimer’s disease it is also associated with Down’s 
syndrome (SDAT). 
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Pathophysiology
The underlying cause of Alzheimer’s disease is unknown. The possible 
theories of the pathogenesis of the disease include:
∑ Lossx of Choline acetyltransferase induced neurotransmitter stimulationt.
∑ Apolipoprotein –E alterations, to which beta amyloid binds.
∑ Mutation for encoding amyloid precursor protein.
∑ Excessive influx of calcium ions as a result of the pathologic activation NMDA receptor.
Early onset FAD: Caused as a result of atleast 3 gene defects; presenilin 1 (PSEN1) gene on 
chromosome 14, amyloid precursor protein (APP) gene on 21 and presenilin 2 (PSEN2) gene on 
chromosome 1.
Late onset FAD: caused due to the defective gene apolipoprotein E (APOE4) on chromosome 
19. 
All these mechanisms may result in the aggregation and precipitation of 
amyloid which is insoluble in nature in brain tissues and blood vessels. The disease is linked to 
a lysosomal pathway which yields beta amyloid (neurotoxic) as a result of the breakdown of 
amyloid precursor protein. Alzheimer’s disease has an autoimmune cause as well as the 
presence of antibrain antibodies.
Another hypothesis regarding the disease is the attachment of complement 
proteins to the formed plaques leading to the microglial cell attraction to the plaques. These 
cells release toxins inorder to destroy the plaques which predispose to the disease. The disease 
development depends upon the changes that occur as a result of ageing and injury.
Clinical manifestations 
∑ Forgetfulness and Emotional upset
∑ Disorientation and Confusions
∑ Inability to concentrate 
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∑ Problem solving and abstraction declines
∑ Lack of judgment etc [17] [18] [19].
AFFECTIVE DISORDERS
They are exemplified by mood regulation. The monoamine hypothesis proposes that, the 
mood disorders are caused due to the reduced norepinepinephrine and /or serotonin levels. It is 
also suggested that these disorders reflect complex disturbances rather than simple chemical 
imbalance. The major affective disorders include;
1. Major depressive disorder 
2. Bipolar Affective Disorder
1. Major depressive disorder (MDD)
Characterized by recurrent episodes of social isolation (including 
decreased ability to experience pleasure, apathy, feelings of worthlessness), depressed mood, 
and somatic symptoms (alterations in sleep and appetite, reduced energy, speech latency, muscle 
pain and slowing of movement. It is precipitated by major life stresses or occurs spontaneously. 
A single depressive episode is believed to last for 2 weeks or longer and to interfere with the 
patient’s day to day activity.
Subtypes of MDD:
∑ Melancholic depression (typical depression)
∑ Psychotic depression
∑ Atypical depression
Melancholic depression (typical depression)
Characterized by the inability to go back to sleep after waking up early in 
the morning, prominent social detachment etc. 
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Atypical depression
It is characterized by symptoms opposite to the signs shown by patients 
with typical depression. They will exhibit increased appetite with hypersomnia. They are capable 
of enjoying brief period’s pleasure and indulge in pleasure seeking activities.
Psychotic depression
It is the major disabling and severe form of depression. 
2. Bipolar Affective Disorder (BPAD)
It is characterized by mood swing from hypomania to depression. Usually the 
dominant characteristic features of BPAD include noteworthy, incapacitating depression. Before 
the attack by manic episodes, usually the patient is struck by depressive episodes.
Drug therapy:
Antidepressant Drugs
1. Monoamine oxidase inhibitors (MAOI)
∑ Irreversible:
Hydrazine derivatives: Iproniazid, isocarboxazid
Nonhydrazine derivatives: Tranylcypromine
∑ Reversible: Moclobemide, Clorgyline
2. Serotonin – Noradrenaline reuptake inhibitors
∑ Tricyclic Antidepressants
NA- reuptake inhibitors: Amitryptyline
5HT- reuptake inhibitors: Clomipramine
∑ Selective 5HT-NA reuptake inhibitors (SNRI): Duloxetine, Venlafaxine
3. Selective serotonin reuptake inhibitors (SSRI): Fluoxetine, Citalopram
4. Selective Noradrenaline reuptake inhibitors (NARI): Reboxetine
5. 5-HT2 receptor blockers: Trazodone
6. Miscellaneous 
Unicyclic: Bupropion
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Tetracyclic: Amoxapine [20] [21] [22].
ANXIETY DISORDERS
Anxiety may be defined as an unpleasant state of mental uneasiness, 
apprehension, nervousness and obsession or concern about something uncertain. The major 
symptoms include; arousal, tenseness, increased autonomic activity like respiration, blood 
pressure and heart rate. Tightness in chest, palpitations, perspirations etc. it is a common 
symptom in a variety of distinct mental illnesses and is a predominant symptom in panic 
disorders, phobias and obsessive compulsive disorder.
The major types of anxiety include:
Panic disorder:  Psychiatric condition associated with multiple disabling panic attacks. In 
between the panic attacks, an excessive time is spent by the individual in thinking about future 
panic attacks.
Generalized anxiety disorder: It is characterized by persistent and excessive worries. The 
patient worries about various life events such as job performances, marital status, money, social 
status etc.
Posttraumatic stress disorder: Caused due to the exposure of individual to life-threatening or 
terrifying life events. The individual re-experiences the traumatic event as flashbacks or as 
intrusive recollections.
Obsessive – compulsive disorders: The root cause of the disorder is intrusive, repetitive 
compulsions and / or thoughts. Marked distress is the hallmark of this disorder. There occur 
irrational thoughts and acts which impair normal functioning. 
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Drug therapy:
Antianxiety Drugs:
∑ Benzodiazepines: Diazepam, lorazepam, alprazolam
∑ Azapironees: Buspirone
∑ Sedative antihistaminic: Hydroxyzine
∑ Beta blocker: Propranolol [23] [24] [25].
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2.  REVIEW OF LITERATURE 
The following studies on the constituents of the Formulation were reported in literature.
• Shalini Adiga et al., (2010) evaluated the effect of Punica granatum peel extract on 
learning and memory in rats. At the doses used (50 and 100mg/kg), there is an explicit 
trend of memory advancement by Punica granatum peel with effects being more 
noticeable on spatial learning tendency and long term memory than on retention capacity
at a dose of 100mg/kg [26].
• Amin Ataie et al., (2010) studied the Neuroprotective effects of the polyphenolic 
antioxidant agent, Curcumin, against homocysteine-induced cognitive impairment and 
oxidative stress in rat. In this study,the neuroprotective and antioxidant properties of the 
extract was evaluated against the neurotoxicity induced by Homocysteine. The results 
showed that the Intraperitonial injection of curcumin (5 and 50mg/kg) and intra-
hippocampal injection of homocysteine (0.2µmol/ml) for a specified time period 
remarkably reduced the level of Malondialdehyde and super oxide anion (increased by 
homocysteine injection). The histopathological analysis indicated the ability of curcumin 
extract to control the reduction in hippocampus cell count, thereby reversing the toxic 
effect of homocysteine. Thus they concluded that the polyphenol treatment (Curcumin) 
showed a significant improvement in learning and memory deficits by protecting the 
nervous system against homocysteine toxicity [27]. 
• Justyna Pyrzanowska et al., (2010) evaluated the influence of the long-term 
administration of Curcuma longa extract on learning and spatial memory as well as the 
concentration of brain neurotransmitters and level of plasma corticosterone in aged 24
month old male Wistar rats using Morris water maze paradigm. The extract at doses 10 
and 50mg/kg orally for 2 months showed noteworthy differences in brain monoamines 
and amino acid levels between groups. The result showed an enhanced learning ability 
and spatial memory, modulation of central serotoninergic system activity and increased 
tolerance to stress in animals after curcuma extract treatment. The extract showed hopeful 
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reduction in glutamate induced excitotoxicity and hippocampus neuronal degeneration 
[28]. 
• Hanumanthachar Joshi et al., (2006) studied the antiamnesic effects of Desmodium 
gangeticum to evaluate the capacity of the plant as a nootropic agent using exteroceptive 
behavioral models like elevated plus maze, passive avoidance paradigm and interoceptive 
behavioral models including Scopolamine induced amnesia and ageing induced amnesia. 
The treatment with the extract for seven successive days at doses (50, 100, and 
200mg/kg. p. o.) reversed the amnesia induced by scopolamine (0.4mg/kg. i. p.) and 
natural ageing. The extract was also found to reduce the whole brain acetylcholine 
esterase activity [29]. 
• Subha Rastogi et al., (2011) carried out a study on the ethnomedicinal, phytochemical 
and pharmacological profile of Desmodium gangeticum (L.) DC. and Desmodium 
adscendens (Sw.) DC and concluded that Desmodium gangeticum and Desmodium 
adscendens have emerged as a good source of traditional medicine. Desmodium 
gangeticum possessed the ability to scavenge the free radicals generated during ischaemia 
and ischaemic reperfusion thereby preserving the mitochondrial respiratory enzymes that 
eventually led to cardio-protection, and is a promising antiamnesic or nootropic agent 
[30]. 
• Gaurav Gupta et al., (2012) evaluated the Antidepressant-like activity of Embelin 
isolated from Embelia ribes. Extracted Embelin at doses (2.5 and 5 mg/kg) was 
administered intraperitonially and the anti-depressant activity of the extract was evaluated 
using Tail suspension test and Forced swim test. The extracted Embelin at a dose of 5 
mg/kg showed comparable decrease in immobility with that of the standard drug 
Imipramine (15 mg/kg) [31]. 
• Shete R V et al., (2010) studied the Nootropic effect of Hemidesmus indicus in mice. The 
learning and memory parameters were measured using elevated plus maze and passive 
avoidance paradigm. Thus from the study it was concluded that the n-butanol fraction of 
H. indicus extract significantly improved learning and memory at doses (3, 10 and 30 
mg/kg p. o.). Hence useful as a memory restorative agent in the treatment of dementia 
seen in the Alzheimer’s disease [32]. 
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• David J. Loren et al., (2005) carried out a study entitled Maternal Dietary 
Supplementation with Pomegranate Juice Is Neuroprotective in an Animal Model of 
Neonatal Hypoxic-Ischemic Brain Injury. Pregnant mice were provided drinking fluid 
that contained either a high dose of pomegranate juice concentrate diluted in the ratio of 
1:80 in deionized, filtered water estimated to provide 32 μmol of polyphenols per day, a 
middle dose of pomegranate juice (1:160 dilution of pomegranate juice concentrate 
estimated to provide 16 μmol of polyphenols per day), or a low dose of pomegranate 
juice (1:320 dilution of pomegranate juice concentrate estimated to provide 8 μmol of 
polyphenols per day). Sugar water control was prepared to replicate the sugar mixture 
and content of the middle dose dilution of pomegranate juice concentrate. The results 
revealed that pups in litters that were exposed to low-, middle-, and high-dose 
pomegranate juice had much less brain injury. The group that received high-dose 
pomegranate juice had >50% less tissue injury compared with the plain water control 
group, and the effect in this group was of highest statistical significance [33]. 
• Chitra V et al., (2009) studied the neroprotective activity of Rubia cordifolia on β-
amyloid Induced Cognitive Dysfunction in Mice using various animal models. The study 
revealed the ability of the plant extract to reduce β- amyloid induced cognitive and 
memory dysfunction. It was concluded that the extract possessed significant protective 
effect on neurodegeneration and showed promising improvement in the memory retention 
activity which made the plant effective in treating Alzheimer’s disease [34].
• Jiban Debnath et al., (2011) evaluated the Anti-stress Effects of Terminalia chebula. The 
animal models used for the study were anoxia stress tolerance and forced swimming test 
in mice, as well as cold resistant stress and immobilization test in rats. Terminalia 
chebula was administered at doses of 200 and 500 mg/kg and the reference standard used 
was Withania somnifera. The results showed that the ethanolic extracts of T. chebula 
appreciably increased the swim endurance and anoxia stress tolerance time and hence 
concluded the anti-stress activity of the plant by preventing stress induced elevated levels 
of biochemical and hematological changes and the variation in organ weights [35]. 
• Nitesh Garg et al., (2012) carried out the phytochemical studies and anti anxiey activity 
of uraria picta leaves. The study revealed the presence of phytoconstituents like 
flavonoids, steroids, triterpinoids and the plant showed good CNS related 
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pharmacological activities like antiaxiety activity at the doses of 400mg/kg and 
600mg/kg. The extract was found to be a promising nootropic agent [36]. 
• Md. Shalam et al., (2009) evaluated the Neuropharmacological profile of Trans-01 a 
polyherbal formulation in mice. Trans-01, a polyherbal formulation consisting of 
Valeriana wallichi as a mojor constituent was explored for its CNS activity. The 
experimental models used for evaluating the nootropic activity were Hole board test, 
pentobarbitone sodium induced sleeping time and rotarod test. The formulation at 200, 
400 and 600 mg/kg showed dose dependant anti-anxiety activity in hole board test and 
irrelevant effect on rotarod test and pentobarbitone induced sleeping time. The 
formulation at a dose of 800 mg/kg showed promising anxiolytic activity in hole board 
test, reduced motor coordination and skeletal muscle relaxant property in rotarod test 
[37]. 
• Amrendra Kumar Chaudhary et al., (2013) evaluated the cognitive enhancement in aged 
mice after chronic administration of Cedrus deodara Loud and Pinus roxburghii Sarg.
The effect of oil and chloroform extracts of the plant on learning and memory was 
studied using the Morris water maze paradigm. Out of the oil and chloroform extracts of 
Cedrus deodara, chloroform extract (100 mg/kg) was found to reduce the level of 
malondialdehyde (MDA) with a simultaneous significant increase in the level of 
glutathione (GSH) in both the frontal cortex and hippocampus. The study revealed that 
owing to the strong anti-oxidant activity of the extract, the plant showed promising 
memory enhancing effect [38].  
• Pinkesh K Tiwari et al., (2012) studied the anticonvulsant activity of Mesua ferrea Linn
ethanolic flower extract in Albino mice at doses 200, 400 and 600 mg/kg p. o using 
Maximum Electroshock Seizure (MES) test. The results showed a dose dependant 
reduction in the duration of hind limb tonic extension (HLTE), which confirmed the plant 
to be a promising anticonvulsant [39].
• Edula Vinitha et al., (2014) evaluated the Neuroprotective effect of Prunus avium on 
streptozotocin induced neurotoxicity in mice. The neurobehavioral changes were studied 
using elevated plus maze and Y-maze models and the biochemical markers such as 
acetylcholinesterase (AChE), tissue nitrite, corticosterone, thiobarbituric reactive 
substances (TBARS) antioxidants like glutathione peroxidase (GPx), superoxide 
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dismutase (SOD) and catalase were estimated. The results of the study exposed the 
efficacy of the extract in averting neurotoxicity and significant diminution of AChE, 
corticosterone, TBARS, tissue nitrite levels [40].
• Singh Karam et al., (2012) carried out a study entitled An Ayurvedic insight towards 
epilepsy. The study revealed the effectiveness of selected plants like Saussurea lappa, 
Rubia cordifolia, Emblica officinalis, Terminalia chebula, Hemidesmus indicus, Curcuma 
longa, Cedrus deodara etc as potent anticonvulsant agent with least side effects and 
effective activity [41].
• Shrinivas K. Kulkarni (2007) studied the possible involvement of L-arginine-nitric oxide 
(NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant 
activity of berberine chloride. The antidepressant activity was assessed in forced-swim 
and tail-suspension tests. The results showed that Berberine (5-20 mg/kg, i.p.) produced a 
drop in immobility period in both the tests. The neurochemical analysis revealed that 
berberine (5 mg/kg, i.p.) augmented the levels of norepinephrine, serotonin or dopamine 
in the mouse whole brain and he concluded that by modulating brain biogenic amines 
(norepinephrine, serotonin or dopamine) Berberine also exerted antidepressant like effect 
in various behavioural paradigms of despair and interaction with the L-arginine-NO-
cGMP pathway involved the antidepressant-like effect of berberine in the forced-swim 
test [42]. 
• Ashwani Kumar et al., (2013) carried out the Estrogenic and Anti-Alzheimer’s studies of 
Zingiber officinalis and Amomum subulatum Roxb. Estrogenic effect was evaluated by 
uterine weight method while effect on learning and memory was studied using elevated 
plus maze method. The results of the study revealed that the Cardamom extract showed 
better estrogenic effect as compared to ginger and reverse trend was observed in case of 
anti-Alzheimer’s activity. Both extracts exhibited considerable improvement in learning 
and memory [43].
• T. Nirmala et al., (2015) reviewed the herbs which exhibited anxiolytic activity in which 
over 40 medicinal plants were tested for their anxiolytic activity using animal models 
including Immobilization induced anxiety, elevated plus maze model, light dark model. 
Hole board test etc. The results showed the ability of the herbs to modulate the 
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neurotransmission process via neurotransmitters including GABA, serotonin, 
noradrenalin etc [44]. 
• Om Prakash Rout et al., (2013) carried out a critical review on the management of 
psychosomatic disorders through Ayurvedic drugs. A number of Ayurvedic drugs and 
their active principles were subjected for evaluation of their nootropic activity. It was 
observed that customarily almost 28 solitary drugs are being used either as a single or in 
combination for the treatment of Unmada, Apasmara, Sanyasa Bhrama, and Murccha. 
Almost 78 lone Indian curative plants and 50 conventional Ayurvedic formulations are 
being used for curing psychosomatic disorders. The medicinal herbs found to produce 
nootropic activity include Callicarpa macrophylla, Emblica officinalis, Terminalia 
bellerica, Nymphea stellata, Curcuma longa etc. Active constituents extracted from 
explicit parts of 14 curative plants are being used for managing mental health problems 
and nearly 46 medicinal plants were reported to be pharmacologically effective as 
anxiolytic, adaptogenic and anti-stress agents [45]. 
• B. Vinutha et al., (2007) reviewed the acetycholinesterase inhibitory activity of 
traditionally used medicinal plants and concluded that conventionally used medicinal 
plants like Alpinia galanga, Rubia cordifolia, Embelia ribes, Emblica officinalis, 
Terminalia chebula, Punica granatum etc showed significant acetylcholinesterase 
inhibitory activity [46]. 
• X. Xia et al., (2007) evaluated the Behavioral, neurochemical and neuroendocrine effects 
of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test. The 
administration of ethanolic extract of Curcuma longa orally for 21 consecutive days 
resulted in a reduction in the duration of immobility in forced swim test. The results 
confirmed the promising anti-depressant activity of the plant [47]. 
• Khandelwal Vinoth Kumar Megraj et al., (2011) studied the biological activities of some 
traditional medicinal plants which include plants like Emblica officinalis, Curcuma 
longa, Hemidesmus indicus, Adhatoda vasica, Aegle marmelos, Aloe vera, Andrographis 
paniculata, Asparagus adscendents, Cinnamomum tamala, Coriandrum sativum, 
Cuminum cyminum etc. The results confirmed the promising nootropic activity of the 
plants. It was concluded that the reported activity may be shown by either the whole 
plant, or a part of the plant, or a particular extract, or isolated compounds [48]. 
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• Sokindra Kumar et al., (2008) evaluated the protective effects of Punica granatum seeds 
extract against ageing and scopolamine induced cognitive impairments in mice. The 
results revealed the ability of ethanolic extract of the plant to overturn the age induced or 
scopolamine induced retention deficits in elevated plus maze and one trial step-down type 
passive avoidance [49]. 
• Jagdeep S. Dua et al., (2009) studied the role of traditional medicine in 
neuropsychopharmacology. The study was done using plants like Valeriana wallichii, 
Curcuma longa, Terminalia chebula etc. From the results, it was understood that the 
aqueous extract of plant of Curcuma longa (Turmeric) demonstrated activity in mice 
following oral administration, which was associated with the inhibition of brain 
monoamine oxidase A. Curcumin, the major constituent from this plant was shown to be 
neuroprotective against ethanol induced brain injury. The results further showed the 
ability of these plants to treat various neurological disorders [50]. 
• Talha Jawaid et al., (2011) reviewed the anti-depressant activity of medicinal plants like 
Curcuma longa, Berberis aristata, Emblica Officinalis, Valeriana wallichi, Clitoria 
ternatea etc and reported that herbal plants are very rich source of substance which are
responsible for increasing the antidepressant activity. The plants used for the study 
exhibited promising nootropic activity [51].
• R. S. Ramsewak et al., (2000) evaluated the antioxidant activity of Curcuma longa. The 
results showed significant inhibition of liposome peroxidation by curcumins I-III at 
aconcentration of 100 µg/ml. Curcumins also exhibited promising inhibition of COX-I 
and COX-II enzymes at doses 125 µg/ml and 125 mg/ml respectively [52].
• Ravindra G. Mali et al., (2008) reviewed the phytochemistry, ethnobotany, 
pharmacologic profile of Baliospermum montanum and found out that the plant has the 
ability to reverse dropsy [53].
• Nabila Benariba et al., (2013) carried out the Phytochemical screening and free radical 
scavenging activity of Citrullus colocynthis and concluded that the plant extract at a 
concentration of 2000 µg/ml showed significant free radical scavenging activity by using 
DPPH method[54]. 
• Nithya Narayanaswamy et al., (2011) studied the anti-oxidant properties of Solanum 
indicum using DPPH radical scavenging activity. The total phenolic content of the plant 
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extract was also measured. The herbal extracts of the plants were prepared with the 
solvents namely water and ethanol at 5 % concentration levels. The results showed that
the plant extract exhibited the DPPH radical scavenging competence ranging from 70-90 
% in aqueous solvent at this particular concentration [55].
• Bibhabasu Hazra et al., (2010) carried out a comparative study on the anti-oxidant 
potential of the plants Terminalia chebula, Terminalia bellerica and Emblica officinalis
and concluded that the free radical scavenging activity followed the order Terminalia 
chebula showing most promising scavenging activity followed by Emblica officinalis and 
then Terminalia bellerica. The flavanoid content of the plant also followed the same 
order but the plant containing highest concentration of phenol was found to be Emblica 
officinalis followed by Terminalia bellerica and finally Terminalia chebula. The study 
revealed the fact that 70% methanolic extract of the fruits of the 3 plants showed 
significant anti-oxidant potential [56].
• Mariel Marder et al., (2003) studied the CNS activity of Valeriana flavanoids obtained 
from various Valeriana species. Sodium thiopental-induced sleeping-time assay, 
Locomotor activity assay, Holeboard test, Horizontal wire test and Elevated plus-maze 
test were used to assess the activity of the plant. The results of the study revealed that the 
plant possess significant nootropic activity [57].
• Obed Ahmed Ansari et al., (2013) studied the anti-dementing activity of Saraswata 
ghrita, a nootropic formulation from Ayurveda, and concluded that the formulation was 
found to manage dementia in Alzheimer’s disease [58].
• Gaurav Gupta et al., (2012) evaluated the Sedative, antiepileptic and antipsychotic effects 
of Viscum album L. (Loranthaceae) in mice and rats. PTZ-induced convulsion,
Pentobarbital sleeping time and Apomorphine-induced stereotypy were the models used 
to assess the activity. The results suggested that the plant exhibited promising sedative, 
antiepileptic and antipsychotic activity in mice and rats [59].
• F. Cı´cero Bezerra Felipe et al., (2007) studied the anxiolytic and anti-depressant activity 
of Piplartine using Rota rod, elevated plus maze, pentylenetetrazole (PTZ)-induced 
seizures, forced swimming tests and open field test as animal model. The results revealed 
the promising anxiolytic and anti-depressant activity of the plant extract containing the 
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alkaloid piplartine which makes it an effective agent for treating anxiety and depression 
[60].
• Girish S. Achliya et al., (2004) evaluated the anti convulsant and sedative properties of 
the formulation Unmadnashak Ghrita using animal models including motor coordination 
test, locomotor activity test, PTZ- induced convulsion, Pentobarbital induced sleeping 
time etc. The results of the study revealed that the formulation showed CNS-depressant 
activity in gross behavioural test, potentiated pentobarbitone sleeping time and there was 
significant decrease in spontaneous locomotor count in mice. The formulation also 
antagonized the behavioral effects of CNS-stimulant drug amphetamine, and showed 
analgesic effect in mice. UG failed to affect the motor coordination test. The formulation 
also protected mice from MES and PTZ induced convulsions. These results suggest that 
UG has CNS-depressant and anticonvulsant activity in mice. [61].
• Biyani D. M et al., (2013) studied the CNS activity of Asthamangal Ghrita which is an 
Ayurvedic formulation made up of ghee (base) along with Hemidesmus indicus, Rock 
salt, Acorus calamus, Centella asiatica, Brassica campestris, Saussurea lappa and Piper 
longum. The activity was evaluated using various animal models which revealed the 
efficacy of the formulation as a promising nootropic agent [62].
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3. FORMULATION PROFILE
3. 1. Name
Kalyanakam Kashayam
3. 2. Description
Concentrated decoction prepared out of herbal ingredients, which consist of water soluble 
active principles.
3. 3. Indication
Neurological disorders, epilepsy, psychosis and anxiety.
3. 4. Dose
Kashayam 5 – 15 ml diluted with 15 – 45 ml of water twice daily before food or as directed 
by physician.
3. 5. Side effects 
No known side effects, over dose may produce gastric irritation [63]. 
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3. 6. Ingredients
Table-2: Composition of Kalyanakam Kashayam
Sl no. Sanskrit Name Botanical Name
1 Haritaki Terminalia chebula
2 Vibhitaki Terminalia bellirica
3 Amalaki Emblica officinalis
4 Vishala Citrulus cholocynthis
5 Bhadra ela Amomum subulatum
6 Devadaru Cedrus deodara
7 Elavaluka Prunus avium
8 Sariva Hemidesmus indicus
9 Haridra Curcuma longa
10 Daruharidra Berberis aristata
11 Shalaparni Desmodium gangeticum
12 Prishnaparni Uraria picta
13 Phalini Callicarpa macrophylla
14 Nata Valeriana wallichi
15 Brihati Solanum indicum
16 Kushta Saussurea lappa
17 Manjishta Rubia cordifolia
18 Nagakesara Mesua ferrea
19 Dadimaphalatwak Punica granatum
20 Agaru Alpinia galanga 
21 Vella Embelia ribes
22 Talisapatra Abbies webbiana
23 Ela Elettaria cardamomum
24 Malati Jasminum sambac
25 Utpala Nymphea stellata
26 Danti Baliospermum montanum
27 Padmaka Prunus poddum
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3. 7. Description of individual ingredients
∑ Terminalia chebula and Terminalia bellirica: The plant consists of Chebulin, a coumarin 
conjugated with gallic acid, chebulosides I and II, arjungenin, arjunglucoside I, 
punicalagin, ellagic acid, chebulinic acid, gallic acid, ethyl gallate etc and is used as 
laxative, purgative, appetite stimulant, rejuvenate, astringent, asthma, etc and fruits play 
an imperative role in endorsing memory and intelligence [64]. 
∑ Emblica officinalis: Chief chemical components are emblicanin A&B, pedunculagin, 
Vitamin C, puniglucanin, glutamic acid, aspartic acid, proline, alanine, ellagic acid 
hexahydroxy-diphenic acid and lysine. The activities of the plant includes antipyretic, 
analgesic, anti-tussive, anti-atherogenic, adaptogenic, cardioprotective, gastroprotective, 
anti-anaemia, wound healing, anti-hypercholesterolemia, anti-atherosclerotic, 
hepatoprotective, neuroprotective properties, anti-diarrhoeal and nephroprotective [65]. 
∑ Citrulus cholocynthis: Fatty acids such as myristic, palmitic, stearic, oleic, linoleic and 
Linolenic acid, Flavone c-glucosides, iso-vitexin, iso-orientin and iso-orientin 3’-
methylether, while the aerial parts contain three C-p-hydroxy benzyl derivatives viz., 8-C-
p-hydroxybenzylisovitexin, 6-C-p-hydroxybenzylvitexin and 8-C-p 
hydroxybenzylisovitexin 4'-O-glucoside are the major constituents of the plant. It was 
reported to possess activities like purgative, anti-diabetic, anti-inflammatory, analgesic,
abortifacient, hair growth-promoting and anti-epileptic. It is combined with several other 
cathartics to relieve health troubles such as obstinate edema, amenorrhea, jaundice, worm 
infestation, bronchitis, abdominal disorders, asthma, and cerebral derangements [66].
∑ Amomum subulatum: The uses of the plant are; relief of nausea, particularly morning 
sickness in pregnancy, reinforces digestion and exterminates the bacteria accountable for 
bad breath. It also clears congestion from colds, allergies and flu. Cardamom was reported 
as the best source of a phytochemical called cineole, which calms your nerves and clears 
our head. It consists of monoterpenic hydrocarbons (16.3%), oxygenated monoterpenes 
(75.2%) and sesquiterpenes (6.3%). Its major constituents are 1,8-cineole (61.3%), α-
terpineol, α- and β-pinene and allo-aromadendrene [67].
Formulation profile 
Department of Pharmacology Page 32
∑ Prunus avium: The plant is composed of chemical constituents including polyphenolic 
anthocyanin glycosides, melatonin, lutein, trace elements like copper, zinc, potassium etc. 
Melatonin has a soothening effect on nerves of the brain which relieves neurosis, 
insomnia, headache, fibromyalgia, heart diseases etc. It is a potent anti-inflammatory 
agent [68].
∑ Hemidesmus indicus: The plant is rich in coumarinolignoids, Hemidesminine, hemidesmin 
I and hemidesmin II50. It is effective as a tranquilizer, anti-inflammatory and anti-
bacterial agent. It cools urinary tract, alleviates kidney disorders, skin diseases, epileptic 
seizures, high stress etc. improves fertility, helps in achieving easy dream lucidity during 
REM sleep [69].
∑ Curcuma longa: Curcumin is the principal constituent present in the plant and the plant is 
used as an anti-inflammatory, anti-cancerous, anti-allergic agent etc. It is used to cure 
heart burns, ulcerative colitis, bronchitis, headache and leprosy. It is found to be effective 
in treating Alzheimer’s disease and is a cognitive enhancer. It is also used as an anti-
depressant [70].
∑ Berberis aristata: Berberine, palmatine, columbamine are the principal alkaloids present 
in the plant. The reported activities of the plant includes, astringent, bitter tonic, 
anaesthetic, in treating eye diseases etc [71].  
∑ Uraria picta: Alkaloids, glycosides, steroids, tannis, flavanoides and proteins are the 
major constituents of the plant. The plant is used in the treatment of delirium, psychosis, 
anxiety, ulcer, dysentery, asthma, bleeding piles, gonorrhea etc. heart diseases and snake 
bites are effectively treated by this plant [72].
∑ Callicarpa macrophylla: It is used for treating rheumatic pain, headache, stomatitis, 
genitourinary diseases, giddiness, emesis, leprosy,mouth and tongue sores. The activities 
are ought to be due to the presence of calliterpenone and its monoacetate, fatty acids, 
betasitosterol and its beta-D-glucoside [73].
∑ Valeriana wallichi: Chatarine and valerianine are the major constituents of the plant. The 
activities of the plant include anti-hypertensive, anti-stress and anti-anxiety activity. It is 
used to treat insomnia, nervous disorders, muscle spasms, menustral cramps, hysteria, 
asthma etc [74].
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∑ Solanum indicum: Wax, fatty acids, alkaloid solanine and solanidine, disogenin, 
lanosterol, β-sitosterol, solasornine, solamargine and solasidine etc are the chief chemical 
constituents of the plant. It is traditionally used in the treatment of sleep disorders, body 
and toothaches etc. The plant is famous for its narcotic properties and is used as a tonic. It 
is used as digestive and stomachic too [75].
∑ Saussurea lappa: The active constituents include palmitic acid, beta sitosterol, 
cynaropicrine, costunolide, alkaloid saussurine etc. the major uses of the plant are bitter, 
stomachic, diaphoretic, diuretic, disinfectant and is used to treat leprosy, hysteria, general 
debility, jaundice and cardiac disorders [76].
∑ Rubia cordifolia: The plant root is reported to be rich in resinous and extractive matter, 
gum, sugar, colouring matter. The principal constituent present is purpurine, glycoside 
manjistin, xanthine, garancin etc. the activities reported are; To treat Alzheimers disease, 
psychosis, leprosy, used for treating cardiac disorders etc [77].
∑ Mesua ferrea: Mesuol, mesuaxanthole-B, messuaferrol, sitosterol, mesuanic acid, α and β-
amyrin, β sitosterol etc are the major constituents of the plant. The activities of the plant 
includes digestant, carminative, as a brain tonic, to treat hysteria, brain debility, scabies, 
skin disease, pruritis, leprosy, aphrodisiac, vomiting, dysentery and is an expectorant, 
vermicide and cardiac-tonic [78].
∑ Punica granatum: Used for treating heart diseases, Alzheimer’s disease, anaemia, syphilis, 
diabetes, osteoarthritis, atherosclerosis and it is also used as an anti-inflammatory, anti-
viral and anti-cancerous agent. The active constituents of the plant include; polyphenols 
like punicalagins, gallocatechins, polyphenol catechins, prodelphinidines, delphinidines 
and minerals like potassium [79].  
∑ Alpinia galanga: The plant is used as an expectorant, anti-inflammatory, anti-arthritic, 
thermogenic, aromatic, stimulant, stomachic, nervine tonic, asthma, bronchitis, obesity, 
intermittent fever and diabetes [80].  
∑ Embelia ribes: Embelin, Christembine, Homoembelin, Vilangine, Quercitol etc are the 
major constituents present in the plant. It is an effective astringent, stimulant, anti-
infalmmatory, anti-bacterial agent and carminative. It is very effective in treating epilepsy 
and convulsions, ulcers, sore throat, insanity, cardiac failure, nervous debility, headache 
and tumor [81].
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∑ Abbies webbiana: Methanol, Aziridine, flavanoids, glycosides and alkaloids are the 
principal constituents of the plant. It is used as an antibacterial, antimicrobial, antifungal 
agent and also cures cough, asthma, chronic bronchitis and allergic rhinitis [82].
∑ Elettaria cardamomum: the chief constituents of the plant includes protocatechu aldehyde, 
protocatechuic acid, alpha terpinyl acetate, limonene, linalool, cineole, terpenolene, 
myrcene, iron, calcium, copper, potassium etc. The uses of the plant include analgesic, 
anti-depressant and anti-cancerous activity [83].
∑ Jasminum sambac: Mixtures of coumarins, cardiac glycosides, essential oils, flavonoids, 
phenolics, saponins, and steroids are the major constituents of the plants. The medicinal 
properties of the plant includes; antiseptic, sedative, anti-depressant, diaphoretic, 
galactogogue, aphrodisiac, antispasmodic, expectorant, uterine etc. it is used for the 
treatment of eye disorders, jaundice, ulcers and skin diseases [84].
∑ Nymphea stellata: Apomorphine, phytosterols, nuciferin, phosphoesterase, biflavanoids, 
sucrose, fructose, glucose, mannitol, raffinose, galacturonic acid and amino acids are the 
chief constituents of the plant and the activities include euphoric, pain reliever, memory 
enhancer, coolant, bitter, used to treat jaundice, diarrhea, dysentery etc [85].
∑ Baliospermum montanum: Glycoterpenoids, steroids, flavonoids, titerpenoids, diterpenes, 
saponins and flavonoids are the chief chonstituents and the plant is used as an anti-
inflammatory, anti-rheumatic, anti-dropsy, stimulant, purgative, rubefacient etc. It acts as a 
natural wound healer and natural detoxifier of the skin [86].
3. 8. Preparation of Formulation 
The ingredients as described in Table-2 were coarsely powdered and one part of the powder 
was boiled in 16 parts of water. The mixture was then reduced to 4 parts.
3. 9. Method of storage
Store in airtight container in dry place.
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3. 10. Ayurvedic properties
∑ Roga Karma: Unmada (schizhophrenia), apasmara (epilepsy), jwara (fever), shukra 
kshaya (oligospermia), arthawa kshaya (reduced ovum production), medha kshaya (loss 
of memory and intelligence), pandu (discoloration of skin) and agnimandya (slow 
digestion).
∑ Dosha Karma (active against): Tridoshahara (destroys three doshas)
∑ Agni Karma (digestive function): Deepana (carminative)
∑ Reference: Ashtangahrudayam Uttara Tantra 6/26.
∑ Manufacturer: SNA Oushadhasala Pvt Ltd [87].
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4. AIM AND OBJECTIVES
4. 1. AIM:
Kalyanakam Kashayam, an Ayurvedic concentrated decoction is prepared 
out of 27 different herbal ingredients, which consist of water soluble active principles. It is 
reported to be effective in the treatment of various neurological disorders, epilepsy, psychosis,
anxiety etc. The literature study done so far revealed that there is a lack of scientific data 
concerning the neuropsychopharmacological evaluation of the formulation on different animal 
models. 
The aim of the current study is to assess the neuropsychopharmacological 
effect of the Ayurvedic formulation in Swiss Albino mice.
4. 2. OBJECTIVES:
The objectives of the present study include:
∑ Evaluation of in vitro antioxidant activity of the formulation.
∑ Acute toxicity study of Kalyanakam kashayam.
∑ Neuropsychopharmacological evaluation of the Ayurvedic formulation in Swiss Albino 
mice.
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5. PLAN OF WORK
The present study examines the efficacy of Kalyanakam kashayam an 
Ayurvedic formulation in CNS disorders. The effect of the drug was evaluated on various animal 
models, which was designed as follows.
∑ Literature search and Selection of the Formulation.
∑ Selection of suitable vehicle and dosage of the formulation. 
∑ In vitro Antioxidant study.
∑ Acute toxicity study.
∑ Evaluation of Neuropsychopharmacological effect of Kalyanakam Kashayam using 
different animal models. 
v DEPRESSION
a) Pentobarbitone induced sleeping time
b) Exploratory behavior-Actophotometer
c) Forced swim test
v ANXIETY
a) Elevated plus maze model
b) Hole board test
v NEUROTOXICITY
a) Rotarod test
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v SCHIZOPHRENIA
a) Apomorphine induced stereotypy
v CATATONIA
a) Haloperidol induced catalepsy
v CONVULSION
a) Pentylenetetrazole - Induced Convulsions
∑ Statistical analysis.
∑ Documentation of results.
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6. MATERIALS AND METHODS
6.1. Collection of the Formulation
Kalyanakam Kashayam (Batch number- F0876) was procured from SNA 
Oushadhasala Pvt. Ltd, Kerala.
6. 2. Experimental Animals
Swiss Albino mice (25-30g, either sex) were used for experiments. The 
animals were provided by the Animal House, KMCH College of Pharmacy, Coimbatore, 
Tamilnadu. All the animals were housed for acclimatization for a period of at least 7 days in the 
laboratory animal room prior to study. They were fed with water and standard laboratory food ad 
libitum and were maintained under standard conditions of temperature, humidity and light (12 
hours light/ 12 hours dark cycle). The animals were housed in poly-propylene cages in a group of 
five per cage. It was made sure that all the observations were made in noiseless, diffusely 
illuminated room between 9.00 to 17.00 hr in the experimental room. All the experimental 
procedures were approved by the Institutional Animal Ethical Committee (IAEC) as per 
provisions of Committee for the Purpose of Control and Supervision of Experimental Animals 
(CPCSEA), New Delhi, India.
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6. 3. Requirements
Table-3: Requirements of the study
DRUGS CHEMICALS OTHERS
1. Apomorphine
2.Chlorpromazine
3.Diazepam
4.Haloperidol
5.Pentobarbitone Sodium
6.Pentylenetetrazol
7.Phenytoin
1.ABTS
2. DPPH
3.Phosphate Buffer
4.Quercetin
5. Potassium Persulfate
6.FRAP Reagent
7.Potassium Ferricyanide
8.Ferric Chloride
9.Gallic Acid
10.Sodium Carbonate
11.Folin Ciocalteau Reagent
1.Distilled water
2.Sterile water for injection
3.Normal saline
4.Syringe
5.Needle
6.Gloves
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7. EXPERIMENT DESIGN
∑ In-Vitro Anti-oxidant assay
∑ Acute Toxicity study
∑ Animal study
7. 1. In-Vitro Antioxidant Assay 
7. 1. 1. DPPH radical scavenging activity [88] [89]
The free radical scavenging activity of the formulation was determined by 
DPPH method. 
REAGENTS:
∑ 0.3mM DPPH (1, 1-diphenyl-2-picrylhydrazyl)
∑ Ethanol
∑ Quercetin(1mg/ml)
∑ Formulation(0.999mg/ml)
PRINCIPLE:
The reducing agent or the anti-oxidant reduces 1, 1- diphenyl 
picrylhydrazyl (purple chromogen radical DPPH•) to a hydrazine derivative (pale yellow). The 
absorbance of the mixture is measured at 519 nm and the decrease in absorbance of DPPH 
chromophore indicates a superior scavenging activity. 
DPPH      +    H-A                                         DPPH-H     +     (A)
(Purple) (Yellow)
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PROCEDURE:
DPPH radical scavenging assay was carried out spectrophotometrically. 
1ml of 0.3mM ethanolic solution of DPPH was mixed with test solution dissolved in water at 
different concentrations like 9.99, 14.985, 19.98, 24.975, 49.95 and 99.9µg/ml.                       
The standard used for the assay was Quercetin (1mg/ml) and an equal 
volume of ethanol was taken as control. The reaction mixture was set aside in a dark room for 20 
minutes. The drop in absorbance value (as a result of quenching of DPPH radical) was measured 
spectrophotometrically at 517nm. The experiment was done in duplicate and a parallel blank was 
also prepared excluding the sample/standard compound. The percentage inhibition was 
calculated as:
Abs control - Abs sample
Percentage inhibition (I %)   =                                         X 100
Abs control
Where;
‘Abscontrol’= The absorbance of the control
‘Atest’ = The absorbance of sample/ standard.
IC50 value of the sample was determined from percentage inhibition versus 
concentration curve. The lower IC50 value indicates a better radical scavenging activity.
7. 1. 2. ABTS radical scavenging assay [90] [91]
REAGENTS:
∑ 7 mM ABTS salt [2, 2, - azinobis (3-ethylbenzoline-6-sulfonic acid)]
∑ 2.45mM Potassium per sulphate
∑ Phosphate buffer (pH 7.4)
∑ Quercetin (0.1mg/ml)
∑ Formulation (0.999mg/ml)
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PRINCIPLE:
The assay assesses the ability of the sample/ standard compound to 
scavenge the long-lived cationic chromophore 2, 2’- azinobis- (3-ethylbenzothiazoline-6-
sulphonate) ie (ABTS•+). The absorbance of the chromophore was measured at 734nm and the 
reduction in absorbance of chromophore indicates superior scavenging activity. The hydrogen 
atom donating ability of anti-oxidant helps them to scavenge ABTS•+ generated in aqueous phase 
and was measured spectrophotometrically.
PROCEDURE:
∑ Preparation of phosphate buffer (pH. 7.4): 
0.2M Potassium Dihydrogen Phosphate dissolved in 50ml distilled water 
was mixed with 39.1ml Sodium Hydroxide solution (0.3128g NaOH in 39.1ml distilled water). 
The mixture was made upto a volume of 250ml with distilled water in a standard flask and the 
pH was adjusted to 7.4.
∑ Preparation of ABTS radical cation: 
7mM stock solution of ABTS was mixed with 2.54mM potassium 
persulfate and was kept aside for 12-16 hours in a dark room at room temperature before use. 
ABTS solution was diluted with phosphate buffer (pH 7.4) to an absorbance of 0.7± (0.02) at 
734nm. 
The assay was carried out using different concentrations of the 
formulation like 9.99, 14.985, 19.98, 24.975, 49.95 and 99.9µg/ml and 1 ml ABTS solution was 
added to it. Absorbance of this mixture was read at 734nm after 6 minutes. Control was prepared 
excluding the sample. The standard used in the assay was quercetin at a concentration of 0.1 
mg/ml. The experiment was done in duplicate and a parallel blank was also prepared excluding 
the sample/standard compound. The percentage inhibition was calculated as:
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Abs control - Abs sample
Percentage inhibition (I %)   =                                        X 100
Abs control
Where;
‘Abscontrol’= The absorbance of the control
‘Atest’ = The absorbance of sample/ standard.
IC50 value of the sample was determined from percentage 
inhibition versus concentration curve. The lower IC50 value indicates a better radical scavenging
activity.
7. 1. 3. Ferric Reducing Anti-oxidant Power Assay (FRAP assay) [92] [93]
REAGENTS: 
∑ Acetate buffer (pH. 3.6)
∑ 20mMol TPTZ (2, 4, 6, - tripyridyl-5-triazine solution)
∑ 20mMol Ferric chloride
∑ Quercetin (1mg/ml)
∑ Formulation (0.999mg/ml)
PRINCIPLE:
The basic principle involved in the assay is the reduction of the ferric 
complex of Fe(TPTZ)3+ i.e tripyridyl triazine (a ferroin analogue) to Fe(TPTZ)2+ a ferrous 
complex (intensely blue in colour) in the presence of anti-oxidants in an acidic pH. There will be 
an increase in absorbance value at 593nm. 
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PROCEDURE:
Preparation of FRAP reagent
The reagent was prepared by mixing 25ml 0.2M acetate buffer (pH 3.6), 
2.5ml of 20mMol TPTZ and 2.5 ml of 20mMol Ferric chloride.
The sample/standard compounds were taken in different concentrations 
and was mixed with 0.9ml of the reagent. Absorbance of the mixture was measured 
spectrophotometrically at 595nm after 30 minutes of incubation. Quercetin was used as standard. 
The experiment was done in duplicate and a parallel blank was also prepared excluding the 
sample/standard compound.
7. 1. 4. Reducing power assay [94] [95]
REAGENTS:
∑ Potassium Ferricyanide (1%)
∑ Ferric chloride (0.1%)
∑ 0.2M Phosphate buffer (pH. 6.6)
∑ Quercetin(1mg/ml) 
∑ Formulation (0.999mg/ml)
PRINCIPLE: 
The principle is based on the ability of the sample/standard to react with 
potassium ferricyanide (Fe3+) to form potassium ferrocyanide (Fe2+), which then forms ferric 
ferrous complex upon reaction with ferric chloride. The complex has an absorption maximum at 
700 nm.
Potassium ferricyanide + Ferric chloride Potassium ferrocyanide + ferrous chloride
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PROCEDURE:
Determination of the reducing power of the extract/standard was done 
according to the method of Oyaizu (1986) with some modifications. The formulation at different 
concentrations 9.99, 14.985, 19.98, 24.975, 49.95 and 99.9µg/ml was made up to 250µl with 
distilled water and was treated with 250µl phosphate buffer (0.2M, pH. 6.6) and 250 µl 
potassium ferricyanide (1%). The mixture was then incubated for 20 minutes at 50˚C and 250 µl 
of 10% trichloro acetic acid was added to it. The tubes were centrifuged at 3000 rpm for 10 
minutes and 500 µl of the supernatant was taken, mixed with an equal volume of distilled water 
and added with 100µl of 1% freshly prepared ferric chloride. The absorbance was measured at 
700nm. The experiment was done in duplicate and a parallel blank was also prepared excluding 
the sample/standard compound. The changes in absorbance are proportional to the reductive 
ability. 
7. 2. Total phenolic content [96]
The sample at a concentration of 9.99mg/ml was made upto 1000 µl with 
distilled water. To this mixture, 50 µl of Folin Ciocalteu and 860 µl of distilled water were 
added. The mixture was then incubated for 5 minutes and added 100 µl of sodium carbonate, to 
which 890µl of distilled water was added. The absorbance of the reaction mixture was measured 
at 725nm after 30 minutes of incubation. The experiment was done in duplicate. Gallic acid was 
used as the standard at a concentration of 100mg/ml and a calibration curve was plotted using the 
standard and sample values.
7. 3. Acute toxicity test
Acute oral toxicity study was performed as per OECD-423 guidelines. The 
animals were fasted overnight with free excess of water and were grouped into three consisting 
of 3 animals each, to which the formulation was administered orally at the dose level of 
500mg/kg, 2000mg/kg and 5000mg/kg body weight. They were observed for mortality; toxic 
symptoms such as behavioral changes, locomotor activity, convulsions; direct observation 
parameters such as tremor, convulsion, salivation, diarrhoea, sleep, coma, changes in skin and 
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fur, eyes and mucous membrane, respiratory, circulatory, autonomic and CNS, somatomotor 
activity etc. 
7. 4. ANIMAL STUDY 
7. 4. 1. Animal models of Depression
7. 4. 1. A. Spontaneous Locomotor Activity using Actophotometer [97]
The spontaneous locomotor activity was measured using an actophotometer, which 
operates on photoelectric cells connected in circuit with a counter. A count was recorded and 
displayed, when a beam of light falling on the photocell was interrupted by the movement of the 
animal. Animals were randomly divided into three groups of 5 animals each (either sex). The 
mouse was placed individually inside the actophotometer chamber for noting the basal activity 
score for a period of 10 minutes. The formulation at doses of (250 and 500mg/kg, p. o) and the 
standard drug mephentramine (30mg/kg, i.p.) was given 30 minutes prior to the test after which 
the mice were placed again inside the chamber for measuring the activity.
Experimental design:
Group-1: Standard, received Mephentramine (30mg/kg; i.p.)
Group-2: Test, received Formulation (250mg/kg; p.o. low dose) 
Group-3: Test, received Formulation (500mg/kg; p.o. high dose)
Percentage decrease in activities were calculated for each group using the formula, 
Percentage decrease in activity = (1 – Wa / Wb) ×100
Where, Wa and Wb are the average activity score before and after drug administration 
respectively and calculated.
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7. 4. 1. B. Pentobarbitone Induced Sleeping Time [98]
The test was carried out in four groups of five mice each to which 
pentobarbitone sodium (40mg/kg) was administered intraperitonially, 30 minutes after the 
administration of standard and sample. The animals were observed for loss of righting reflex 
(inability to return to the upright position on all four limbs after the animal was placed on its 
back). The duration of sleep was measured by noting the time interval between the loss and 
recovery of righting reflex.
Experimental design:
Group-1: Control, received Pentobarbitone Sodium (40mg/kg; i.p.)
Group-2: Standard, received Chlorpromazine (3mg/kg; i.p.) + PB  
Group-3: Test, received Formulation (250mg/kg; p.o. low dose) + PB
Group-4: Test, received Formulation (500mg/kg; p.o. high dose) + PB
7. 4. 1. C. Forced Swim Test [99]
The procedures for Forced swim test or Despair swim test were similar to those first described by 
Porsolt., et al. (1977). This test is sensitive to all major classes of antidepressant drugs, hence 
used as an animal model of depression like behaviour. Mice were grouped into three of five 
animals each and were trained individually for three consecutive days (pre-test session). In the 
“test-session” The animals were made to swim individually in an open cylindrical container of 
diameter 20cm and height 50cm, containing 25cm of water at 25˚C, for a test period of 6 
minutes. After a brief period of vigorous activity for about two minutes, mice maintain a typical 
immobile posture. The animals were considered immobile when they float in an upright position, 
making only negligible movements to maintain their head above water. The total duration of 
immobility was recorded and changes in the same were studied for various treatment groups. 
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Experimental design:
Group-1: Standard, received Mephentramine (30mg/kg; i.p.)
Group-2: Test, received Formulation (250mg/kg; p.o. low dose) 
Group-3: Test, received Formulation (500mg/kg; p.o. high dose)
7. 4. 2. Animal models of Anxiety
7. 4. 2. A. Elevated Plus Maze Model of Anxiety [100]
The plus maze for mice (Lister, 1987) consisted of two perpendicular open 
arms (30×5cm) and two closed arms (30×5×15cm) also in perpendicular position. The open and 
closed arms were connected with each other by a central platform (5×5cm). The lateral walls of 
the closed arm and floor of each arm were made of wood. The platform and lateral walls were 
painted in black. The maze was elevated at a height of 45cm above the floor. The animals were 
trained for two consecutive days (pre-test session). In the test-session, 30 minutes after the 
treatment with standard and sample, the animal was placed at the center of the maze with its nose 
facing in the direction of one of the closed arms. The duration of the test period was 10 minutes, 
during which the following parameters were evaluated.
• The number of entries into the open arm.
• The number of entries into the closed arm.
• Time spent in the open arm.
• Time spent in the closed arm.
The experiment was carried out in a sound attenuated room. An entry was counted when the 
animal placed all its four paws on an arm. 
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Experimental design:
Group-1: Control, received Normal saline
Group-2: Standard, received Diazepam (5mg/kg; i.p.)
Group-3: Test, received Formulation (250mg/kg; p.o. low dose) 
Group-4: Test, received Formulation (500mg/kg; p.o. high dose)
7. 4. 2. B. Hole Board Apparatus [101]
Hole board apparatus is a wooden board of the size 40×40cm. The board 
consists of sixteen holes with a diameter of 3cm which are distributed evenly on the board. The 
board is elevated to a particular height (5 cm) from the floor, so that the mouse while poking its 
nose into the hole does not see the bottom. The mice were grouped into four of five animals each 
and were trained for two consecutive days. Thirty minutes after the administration of test and 
standard drugs, the animals were subjected to the test for a period of six minutes and the number 
of counts for nose-poking of treated animals was calculated as percentage of control animals.
Experimental design:
Group-1: Control, received Normal saline
Group-2: Standard, received Diazepam (5mg/kg; i.p.)
Group-3: Test, received Formulation (250mg/kg; p.o. low dose) 
Group-4: Test, received Formulation (500mg/kg; p.o. high dose)
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7. 4. 3. Animal model for Neurotoxicity
7. 4. 3. A. Rota rod Test [102]
Rota rod test was used to evaluate the effect of drug on motor coordination 
in mice. The instrument consists of a horizontal rotating rod (3cm diameter) rotating at a rate of 
25rpm. During the pre-test session, the animals were kept on the rotating rod and those animals 
that had demonstrated their ability to remain on the rotating rod for at least three minute were 
used. In the test session, the experiment was repeated 30 minutes after the administration of 
formulation and standard drugs for a period of 5 minutes the fall off time for each animal was 
recorded. If the animal fails more than once to remain on the rotating rod for 5 minutes was 
considered to be neurotoxic. 
Experimental design:
Group-1: Control, received Normal saline
Group-2: Standard, received Diazepam (5mg/kg; i.p.)
Group-3: Test, received Formulation (250mg/kg; p.o. low dose) 
Group-4: Test, received Formulation (500mg/kg; p.o. high dose)
7. 4. 4. Apomorphine (APM) induced stereotypy in mice [103]
Apomorphine induces a stereotyped behaviour in rodents, characterized by 
licking, sniffing, and gnawing in a repetitive compulsive manner, which is an indication of 
striatal dopaminergic stimulation (Anden et al. 1967; Ernst 1967; Costall and Naylor 1973). The 
animals were grouped into three of five animals each and were trained for three consecutive 
days. In the test groups, mice were treated with the formulation 30 minutes prior to apomorphine 
administration. The test group and control group animals were placed in plastic or glass cage 
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individually and the intensity of stereotyped behavior was assessed at 10 minutes interval for 50 
minutes. Scoring was done as follows:
Score 0: no changes than control.
Score 1: discontinuous sniffing, constant exploratory activity.
Score 2: continuous sniffing, periodic exploratory activity. 
Score 3: continuous sniffing, discontinuous biting, gnawing or licking, very brief periods of
locomotor activity.
Score 4: continuous biting, gnawing or licking, no exploratory activity.
Experimental design:
Group-1: Control, received Apomorphine (1mg/kg; i.p.)
Group-2: Test, received APM + Formulation (250mg/kg; p.o. low dose) 
Group-3: Test, received APM + Formulation (500mg/kg; p.o. high dose)
7. 4. 5. Haloperidol (HP) – induced catalepsy in mice [104]
Catalepsy may be defined as a nervous condition characterized by 
muscular rigidity and fixity of posture regardless of external stimuli, as well as a decreased 
sensitivity to pain. Haloperidol (1mg/kg; i.p.) was used to induce catalepsy. The dose was 
selected as 1mg/kg so that the drug could elicit a moderate degree of catalepsy thereby making 
the detection of either termination or potentiation of the phenomenon.
The animals were grouped and numbered and were trained for three 
successive days. In the test session, animals were treated with formulation 30 minutes prior to 
haloperidol administration and the forelegs of the mice were placed over a horizontal bar 
elevated at a height of 3cm and 5cm respectively after 30 minutes of haloperidol injection. The 
cataleptic behaviour was scored as; point 1 for animals which maintained the imposed posture 
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for at least 20 seconds. For every further 20 seconds the animal maintained the cataleptic 
posture, was awarded with extra point and so on. The endpoint of catalepsy was considered to 
occur when the animal removed both front paws from the horizontal bar or if the animal moved 
its head in an exploratory manner.
Experimental design:
Group-1: Control, received Haloperidol (1mg/kg; i.p.)
Group-2: Test, received HP + Formulation (250mg/kg; p.o. low dose) 
Group-3: Test, received HP + Formulation (500mg/kg; p.o. high dose)
7. 4. 6. Pentylenetetrazol (PTZ) – induced convulsions in mice [105]
The mice were divided into 4 groups of five animals each. The animals 
were injected with Pentylenetetrazol (80mg/kg) 30 minutes after formulation and standard drug 
(Diazepam 4mg/kg) administration. Each animal was placed in separate plastic cage for 
observation. The occurrence of the first generalized clonus (repeated clonic seizures of the fore 
and hind limbs lasting over 5-10 seconds) or jerky movements were recorded during individual 
observation for 30 minutes. The onset and duration both were observed. Reduction in such 
movements was selected as criteria for supporting antiepileptic activity of the drug.
Experimental design:
Group-1: Control, received PTZ (80mg/kg; i.p.)
Group-2: Standard, received Diazepam (4mg/kg; i.p.) + PTZ.
Group-3: Test, received Formulation (250mg/kg; p.o. low dose) + PTZ.
Group-4: Test, received Formulation (500mg/kg; p.o. high dose) + PTZ.
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Department of Pharmacology Page 54
7. 5. Statistical Analysis
All the data were expressed as the mean ± standard error of the mean 
(SEM). The statistical significance of the differences between the groups was analyzed by using 
GraphPad 5.0 software (GraphPad, San Diego, USA) by applying one way Analysis Of Variance 
(ANOVA) followed by Dunnett’s test as post hoc and also Student’s Paired T-test. The values of 
P<0.05 was considered to be statistically significant.
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8. RESULTS 
8. 1. In-Vitro Antioxidant Assay
8. 1. 1. DPPH radical scavenging activity
DPPH radical scavenging assay was performed using different 
concentrations of sample and standard (Quercetin), and the results are shown in table: 4 and 
figure: 1. 
Table-4: Comparitive DPPH radical scavenging activity of Quercetin and formulation.
TREATMENT CONCENTRATION
(µg/ml)
ABSORBANCE PERCENTAGE 
INHIBITION 
(%)
IC50 (µg/ml)
STANDARD 
(QUERCETIN)
5
10
15
20
25
30
1.93 ± 0.021
1.003 ± 0.029
0.8626 ± 0.041
0.5788 ± 0.007
0.2895 ± 0.011
0.2522 ± 0.001
20.23
44.50
66.08
86.82
96.69
97.84
10.38 µg/ml
SAMPLE 9.990
14.985
19.980
24.975
49.950
99.900
1.307 ± 0.015
1.170 ± 0.008
0.908 ± 0.021
0.798 ± 0.007
0.551 ± 0.014
0.153 ± 0.006
35.520
47.390
53.780
60.010
73.430
95.450
17.14µg/ml
Values are expressed as mean ± S.E.M; (n = 2).
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Figure-1: Radical scavenging activity of Quercetin and formulation at various 
concentrations
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The results of the radical scavenging assay are expressed in percentage (%) inhibition of DPPH
free radical.
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8. 1. 2.ABTS radical scavenging assay
ABTS radical scavenging assay was performed using different 
concentrations of sample and standard (Quercetin), and the results are shown in table: 5 and 
figure: 2. 
Table-5: Comparitive ABTS radical scavenging activity of Quercetin and formulation.
TREATMENT CONCENTRATION
(µg/ml)
ABSORBANCE PERCENTAGE 
INHIBITION 
(%)
IC50 (µg/ml)
STANDARD 
(QUERCETIN)
0.5
1.0
1.5
2.0
2.5
3.0
0.2630 ± 0.006
0.2169 ± 0.013
0.1447 ± 0.008
0.0977 ± 0.011
0.0037 ± 0.0035
0.003 ± 0.004
42.50
69.15
79.37
86.64
99.47
99.57
0.6149µg/ml
SAMPLE 9.990
14.985
19.980
24.975
49.950
99.900
0.325 ± 0.014
0.299 ± 0.11
0.238 ± 0.009
0.233 ± 0.007
0.099 ± 0.015
0.004 ± 0.003
49.68
57.38
66.08
66.79
85.89
99.43
11.29µg/ml
Values are expressed as mean ± S.E.M; (n = 2).
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Figure-2: Radical scavenging activity of Quercetin and formulation at various 
concentrations
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The results of the radical scavenging assay expressed in percentage (%) inhibition of ABTS free 
radical.
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8. 1. 3.Ferric Reducing Anti-oxidant Power Assay (FRAP assay)
Ferric reducing anti-oxidant powerassay was performed using different 
concentrations of sample and standard (Quercetin), and the results are shown in table: 6.
Table-6: Comparitive Ferric reducing ability of standard and sample 
TREATMENT CONCENTRATION
(µg/ml)
ABSORBANCE REDUCING POWER 
(%)
STANDARD 
(QUERCETIN)
5
10
15
20
25
30
0.3660 ± 0.0183
0.5748 ± 0.008
0.7873 ± 0.007
1.0687 ± 0.011
1.2997 ± 0.005
1.5494 ± 0.013
51.87
64.20
70.05
81.64
93.18
98.75
SAMPLE 9.990
14.985
19.980
24.975
49.950
99.900
0.2523 ± 0.021
0.2692 ± 0.007
0.2865 ± 0.003
0.3012 ± 0.008
0.3201 ±0.018
0.3403 ± 0.005
43.35
52.95
62.75
71.08
81.875
93.35
Values are expressed as mean ± S.E.M; (n = 2).
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8. 1. 4.Reducing power assay
Reducing power assaywas performed using different concentrations of 
sample and standard (Quercetin), and the results are shown in table: 7. 
Table-7: Comparitive reductive ability of standard and sample
TREATMENT CONCENTRATION
(µg/ml)
ABSORBANCE REDUCING 
POWER (%)
STANDARD 
(QUERCETIN)
5
10
15
20
25
30
0.3357± 0.008
0.3503 ± 0.013
0.3741 ± 0.003
0.4007 ± 0.007
0.4207 ± 0.015
0.4399 ± 0.008
48.73
55.20
65.75
77.53
86.39
94.90
SAMPLE 9.990
14.985
19.980
24.975
49.950
99.900
0.2995 ± 0.019
0.4104 ± 0.003
0.3485 ± 0.021
0.3693 ± 0.034
0.3951 ± 0.004
0.4098 ± 0.003
47.520
54.400
63.620
75.050
81.560
96.320
Values are expressed as mean ± S.E.M; (n = 2).
8. 2.Total phenolic content
Phenolic compounds may contribute directly to the anti oxidative action. 
The total phenolic content of the formulation was quantified using different concentrations of the 
standard (Gallic acid) and the sample. The results are summarized in table-8 and figure-3
.
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Table-8: Determination of Total phenolic content of the formulation
TREATMENT CONCENTRATION
(µg/ml)
ABSORBANCE
STANDARD
(GALLIC ACID)
5
10
15
20
25
30
0.1875
0.3463
0.5799
0.8049
1.0521
1.2629
SAMPLE 9990 1.8811
Figure-3: Total phenolic content of the sample 
The total phenolic content of the sample was found to be 44.29mg/g calculated as Gallic acid 
equivalent.
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8. 3. Acute toxicity test
The acute toxicity test was performed by using the kashyam at 
concentrations 500mg/kg, 2000mg/kg and 5000mg/kg. The observations are summarized in 
table: 9.
Table- 9: Acute toxicity study
Sl. No. Responses
                        FORMULATION
         Head        Body        Tail
Before After Before After Before After
1 Alertness Normal Normal Normal Normal Normal Normal
2 Grooming Absent Absent Absent Absent Absent Absent
3 Touch response Absent Absent Absent Absent Absent Absent
4 Torch response Normal Normal Normal Normal Normal Normal
5 Pain response Normal Normal Normal Normal Normal Normal
6 Tremor Absent Absent Absent Absent Absent Absent
7 Convulsion Absent Absent Absent Absent Absent Absent
8 Righting reflux Normal Normal Normal Normal Normal Normal
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present
11 Corneal reflux Present Present Present Present Present Present
12 Writhing Absent Absent Absent Absent Absent Absent
13 Pupils Normal Normal Normal Normal Normal Normal
14 Urination Normal Normal Normal Normal Normal Normal
15 Salivation Normal Normal Normal Normal Normal Normal
16 Skin colour Normal Normal Normal Normal Normal Normal
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8. 4.  Effect of the Formulation on Spontaneous Locomotor Activity using 
Actophotometer in mice.
The locomotor activity of the animal was assessed using the standard 
(Mephentramine) and formulation. The datas are shown in table-10 and figure -4.
Table – 10:Effect of the Formulation on Spontaneous Locomotor Activity
TREATMENT PHOTOCELL ACTIVITY COUNT
BEFORE AFTER
STANDARD 
(Mephentramine 
30mg/kg)
1463 ± 25.90 1723 ± 15.83***
TEST(LOW) 
(250mg/ml)
1452 ± 17.32 1355 ± 40.70*
TEST(HIGH) 
(500mg/ml)
1109 ± 7.633 1205 ± 21.26***
Values were expressed as mean ± SEM. Statistical analysis was done by student’s t-test (Paired 
t-test).
***P<0.001; *P<0.05; N = 5.
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Figure-4: Effect of the Formulation on Spontaneous Locomotor Activity in mice.
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Effect of the Formulation and standard on Spontaneous Locomotor Activity.Values were 
expressed as mean ± SEM. ***P<0.001; *P<0.05; N = 5.
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8. 5.  Effect of Kayanakam kashayam on Pentobarbitone – induced sleeping
time in mice.
The formulation in the given doses (250mg/kg and 500mg/kg) showed 
significant potentiation of sleeping time induced by Pentobarbitone. The sleeping time of mice 
treated with Pentobarbitone alone and in combination with the standard andformulationare 
shown in table-11 and figure-5.
Table – 11: Effect of the formulation on Pentobarbitone – induced sleeping
Values were expressed as mean ± SEM. Statistical analysis was done by one way ANOVA 
followed by Dunnett’s test as compared to the control group.
***P<0.001; ns= non-significant; N = 5.
TREATMENT SLEEPING TIME(seconds)
CONTROL 2722 ± 15.62
STANDARD (chlorpromazine 3mg/kg) 6526 ± 7.48***
TEST (Low dose-250mg/ml) 2108 ± 7.35ns
TEST (High dose-500mg/ml) 4514 ± 6.00***
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Figure-5: Effect of the formulation on Pentobarbitone – induced sleeping time in mice.
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Effect of the formulation on Pentobarbitone – induced sleeping.Values were expressed as mean ± 
SEM. ***P<0.001; ns= non-significant; N = 5
Where,T1 = Formulation low dose (250 mg/kg)
T2 = Formulation high dose (500 mg/kg)
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8. 6. Effect of the Formulation on Forced swim test in mice
The activity of the formulation was assessed at doses 250 and 500 mg/kg 
and the data are shown in table-12 and figure -6.
Table – 12: Effect of the Formulation on Forced swim test
Values were expressed as mean ± SEM. Statistical analysis was done by Student’s paired t-test.
**P<0.01; *P<0.05; N = 5.
TREATMENT DURATION OF 
IMMOBILITY(SECONDS)
BEFORE AFTER
MEPHENTRAMINE(30mg/kg) 23.40 ± 1.54 12.20 ± 0.66**
TEST(Low dose-250mg/ml) 23.40 ± 0.75 20.20 ± 0.37*
TEST(High dose-500mg/ml) 24.80 ± 1.24 20.00 ± 1.34*
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Figure-6: Effect of the Formulation on Forced swim test in mice
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Effect of the Formulation on Forced swim test.Values were expressed as mean ± SEM. 
**P<0.01; *P<0.05; N = 5.
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8. 7. Effect of the Formulation on Elevated Plus Maze model of anxiety in 
mice
The anti-anxiety effect of the formulation was evaluated at doses 250 and 
500 mg/kg.The data are shown in table-13& 14. 
 Before treatment
Table – 13: Elevated plus maze model of anxietybeforetreatment with formulation
Values were expressed as mean ± SEM. Statistical analysis was done by one way ANOVA 
followed by Dunnett’s test as compared to the control group.ns = non significant; N = 5
TREATMENT MEAN NO OF ENTRIES IN MEAN TIME SPENT IN
OPEN ARM CLOSED ARM OPEN ARM CLOSED ARM
CONTROL 9.60± 1.44 20.20 ± 3.43 59.40 ± 11.07ns 425.8 ± 34.16ns
STANDARD 9.00 ± 1.92ns 23.60 ± 3.89ns 112.8 ± 30.79ns 396.4 ±48.38ns
TEST (Low dose-
250mg/ml)
9.8 ± 1.11ns 21.00 ± 2.51ns 40.00 ± 27.39ns 514.0 ± 33.54ns
TEST(High dose-
500mg/ml)
9.4 ± 2.69ns 21.80 ± 4.35ns 39.60 ± 18.14ns 509.6 ± 29.89ns
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 After treatment
Table – 14: Elevated plus maze model of anxiety after treatment with formulation
TREATMENT MEAN NO OF ENTRIES IN MEAN TIME SPENT IN
OPEN ARM CLOSED ARM OPEN ARM CLOSED ARM
CONTROL 8.0 ± 1.58 10.80 ±2.39 100.6±7.31 429.8±31.92
STANDARD
(Diazepam 
5mg/kg)
10.00 ± 2.92ns 13.60 ± 3.43ns 260.6±12.78 *** 331.2±14.47ns
TEST(Low dose-
250mg/ml)
15.0 ± 1.67ns 14.40 ± 2.40ns 205 ± 20.45** 305.8±33.38ns
TEST(High dose-
500mg/ml)
10.20 ± 1.24ns 12.80 ± 1.49ns 220.2±24. 98 *** 351.6±13.89ns
Values were expressed as mean ± SEM. Statistical analysis was done by one way ANOVA 
followed by Dunnett’s test as compared to the control group.
***P<0.001; **P<0.01; ns= non significant; N = 5.
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8. 8. Effect of Kalyanakam kashayam on Hole board test apparatus in mice
The number of nose poking made by the animal after the administration of 
standard and formulationwere compared with the control group for evaluating the anti-anxiety 
effect of formulation. The data obtained are shown in table-15 and figure -7.
Table – 15: Effect of the sample on nose poking behavior in mice
Values were expressed as mean ± SEM. Statistical analysis was done by Student’s paired t-test.
***P<0.001; *P<0.05; N = 5.
TREATMENT NUMBER OF NOSE POKING
BEFORE AFTER 
CONTROL 28.40 ± 2.293 26.80 ± 2.800 
DIAZEPAM(5mg/kg) 33.60 ± 2.731 8.800 ± 1.497*** 
TEST(Low dose-250mg/ml) 29.80 ± 4.017 15.40 ± 2.482*
TEST(High dose-500mg/ml) 30.80 ± 1.463 13.40 ± 2.205***
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Figure-7: Effect of the Formulation on Hole board test apparatus in mice
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Values were expressed as mean ± SEM. ***P<0.001; *P<0.05; N = 5.
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8. 9. Effect of the Formulation on Motor- coordination test using Rotarod 
apparatus in mice.
The effect of the formulation at doses 250 and 500 mg/kg on motor 
coordination was compared with the control group and the standard group (Diazepam5 mg/kg).
The data obtained are shown in table-16 and figure-8.
Table-16: Effect of the Formulation on Motor- coordination test
Values were expressed as mean ± SEM. Statistical analysis was done by one way ANOVA 
followed by Dunnett’s test as compared to the control group.
***P<0.001; ns= non-significant; N = 5.
TREATMENT FALL OFF TIME(S)
BEFORE AFTER
CONTROL 300 300
DIAZEPAM(5mg/kg) 300 19.80 ± 3.023***
TEST(Low dose-250mg/ml) 300 300ns
TEST(High dose-500mg/ml) 300 290.8 ± 9.200ns
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Figure-8: Effect of the Formulation on Motor- coordination test using Rotarod apparatus 
in mice.
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Effect of the Formulation on Motor- coordination test.Values were expressed as mean ± SEM. 
***P<0.001; ns= non-significant; N = 5.
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8. 10. Effect of Kalyanakam kashayam on Apomorphine induced stereotypy in 
mice.
The stereotypic behavior induced by Apomorphine was assessed in mice, 
after 30 minutes of sample administration at doses 250 and 500 mg/kg and the results obtained 
are shown in table-17 and figure-9.
Table-17: Effect of the Formulation on Apomorphine induced stereotypy
TREATMENT SCORING FOR STEREOTYPIC BEHAVIOUR
10 20 30 40 50
CONTROL 2 ±  0.32 2 ± 0.32 3 2 ±  0.32 1.4 ±  0.24
TEST(Low dose-
250mg/ml)
1.6 ±  0.24ns 2.4 ±  0.24ns 3.2 ±  0.20ns 2.2 ± 0.37ns 1.6 ±  0.24ns
TEST(High dose-
500mg/ml)
1.2 ± 0.20* 1.4 ±  0.24* 2.3 ±  0.51* 1.8 ±  0.49ns 1.4 ± 0.24ns
Values were expressed as mean ± SEM. Statistical analysis was done by one way ANOVA 
followed by Dunnett’s test as compared to the control group.
*P<0.05; ns= non significant; N = 5.
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Figure-9: Effect of the Formulation on Apomorphine induced stereotypy in mice.
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Effect of the Formulation on Apomorphine induced stereotypy.Values were expressed as mean ± 
SEM. *P<0.05; ns= non significant; N = 5.
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8. 11. Effect of the Formulation on Catalepsy induced by Haloperidol in mice
The Formulation at doses 250 and 500 mg/kg were administered for 
evaluating the cataleptic behavior of the animals placed on a horizontal bar at two different 
heights. The reduction in the cataleptic time was assessed. The data obtained are shown in the 
table-18 and figure-12.  
Table-18: Effect of Kalyanakam kashayam on Haloperidol induced catalepsy
TREATMENT CATALEPSY SCORE AT A HEIGHT OF;
3CM 5CM
CONTROL 16.20 ± 0.37 12.60 ± 0.40
TEST(Low dose-250mg/ml) 1.4 ± 0.24*** 1.8 ± 0.20***
TEST(High dose-500mg/ml) 6.4 ± 0.40*** 4.2 ± 0.20***
Values were expressed as mean ± SEM. Statistical analysis was done by one way ANOVA 
followed by Dunnett’s test as compared to the control group.
***P<0.001;N = 5.
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Figure-10: Effect of Kalyanakam kashayam on Haloperidol induced catalepsy.
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Values were expressed as mean ± SEM.***P<0.001;N = 5.
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8. 12. Effect of the Formulation on Pentylenetetrazole induced (PTZ) induced 
convulsions
The effect of the formulation at doses 250 and 500 mg/kg on PTZ induced 
convulsions was compared with the control group and the standard group (Diazepam 4mg/kg).
PTZ was administered at a dose of 80mg/kg to each animal. The observations are given in table-
19 and figure-11 & 12. 
Table-19: Effect of the Formulation on Pentylenetetrazole induced (PTZ) induced 
convulsions
TREATMENT CONVULSIONS/JERKY MOVEMENTS STATUS
OF THE 
ANIMAL
ONSET(S) DURATION(S)
CONTROL + PTZ(80mg/kg) 150 ± 19.69 36.60 ± 9.84 2 died
STANDARD(Diazepam 4mg/kg) + 
PTZ(80mg/kg)
0*** 0*** All alive
TEST(Low dose-250mg/ml) + 
PTZ(80mg/kg)
175 ± 3.76ns 11.20 ± 3.81* 1 died
TEST(High dose-500mg/ml) + 
PTZ(80mg/kg)
133 ± 2.92ns 9.00 ± 2.12** All alive
Values were expressed as mean ± SEM. Statistical analysis was done by one way ANOVA 
followed by Dunnett’s test as compared to the control group.
***P<0.001; **P<0.01; *P<0.05; ns= non significant;N = 5.
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Figure-11: Effect of Kalyanakam kashayam on duration of convulsions, induced by 
Pentylenetetrazole
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Values were expressed as mean ± SEM.***P<0.001; **P<0.01; *P<0.05; ns= non significant; N 
= 5.
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Figure-12: Effect of Kalyanakam kashayam on onset of convulsions, induced by 
Pentylenetetrazole
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Values were expressed as mean ± SEM.***P<0.001; ns= non significant; N = 5.
Discussions
Department of Pharmacology Page 82
9. DISCUSSION
Advance in modern science and technology have contributed to a massive 
advancement in the quality of human life. However, contemporary life stresses are accountable 
for the surge in frequency of diversity of neurologic and psychiatric disorders like anxiety, 
depression, psychosis, schizophrenia, Parkinsonism, Alzheimer’s disease, epilepsy etc. The 
drugs which are currently used for the treatment of these disorders provide symptomatic relief 
rather than altering the course of the disease. The Adverse effect of the drugs ranges from 
exasperating to hindering or potentially incurable effects. Furthermore, the overall functions and 
eminence of life outcome of patients still remains pitiable after treatment. Thus, for the treatment 
of diseases, there is a critical need to search for less toxic and more effective drugs. In this 
context, an increasing number of herbal products have been introduced as an alternative for 
treating these neurolologic and psychiatric disorders. Ayurveda in contrast to the modern western 
medicine considers detoxification as the prime part of treatment and believes in the fact that 
ailments continues cracking up again and again as far as the disease causing factors are 
accessible in the body. The herbal products owing to their less toxicity and adverse effects when 
compared with allopathic treatment have gained widespread utility for treatment of 
neuropsychopharmacological diseases [106] [107].
Thus Herbs and Herbal medicines have stood the test of time for their 
wellbeing, effectiveness, adequacy and lesser side effects. The current study deals with the 
inquiry of the effects of KALYANAKAM KASHAYAM, an Ayurvedic formulation in different 
animal models in the area of neuropsychopharmacology.
Herbal drugs containing radical scavengers are gaining importance in 
treating oxidative stress related diseases [108] [larson]. DPPH radical scavenging activity of the 
formulation at different concentration was compared with the standard Quercetin. Smaller IC50
value indicates a higher antioxidant potential. The IC50 value of the standard and test formulation
was found to be 10.38µg/ml and 17.14µg/ml respectively. The higher IC50 values of the sample 
indicated lesser scavenging activity of the sample when compared with the standard. The study 
showed the promising radical scavenging activity of the formulation due to hydrogen-donating 
ability of the formulation.
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The ability of the formulation to donate hydrogen atoms or electrons to 
scavenge the radical cation was reflected by the decolourization of ABTS radical cation. The 
radical scavenging activity of the formulation was compared with that of the standard and the 
IC50 values obtained were 0.62µg/ml and 11.29µg/ml for standard and formulation respectively. 
The reducing power of the extracts may be due to the biologically active 
compounds in the formulation which possess potent donating abilities [109]. The reducing power 
of the sample was compared with the standard and the reducing power of the formulation and the 
standard drug was found to increase with the increase in concentration of the formulation.
Total phenolic content was determined using the Folin Ciocalteu (FC) 
reagent method with slight modification. Plant phenols constitute the major group of compounds 
that act as primary antioxidant. They can react with active oxygen radicals, such as hydroxyl 
radicals, superoxide anion radicals and lipid peroxyl radicals and inhibit the lipid peroxidation at 
an early stage. [110]. The total phenolic content of the formulation was found to be 44.29mg/g 
calculated as Gallic acid equivalent.
Any medicine, whether synthetic or herbal is anticipated to benefit the 
recipient. To validate the safety and efficacy of the same, toxicity studies are of prime 
importance which predicts the potential toxicity of the medicine in human beings exposed to near 
fatal doses. The dose and extent of toxicity of the formulation was found out by acute toxicity 
studies according to OECD guidelines 423 in mice with the formulation at doses 500mg/kg, 
2000mg/kg and 5000mg/kg. No mortality or morbidity was found till 14 days of study. The dose 
fixed for current study was 250mg/ml as low dose and 500mg/kg as high dose.
The locomotor activity was assessed using the formulation and standard 
drug treated animals [111]. The formulation in the given doses showed noteworthy effect on 
locomotor activity. The formulation at a dose of 500mg/kg showed significant increase in
locomotor activity than that of the formulation at low dose ie 250mg/kg. The action produced by 
the formulation and standard drug was comparable. The results of the study demonstrated the 
formulation to be an effective anti-depressant agent.
The decisive factor for sleep was the loss of righting reflex and the period 
between the loss and revival of righting reflex was used as the indication of hypnotic effect 
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[112]. The formulation at a dose of 500mg/kg showed a promising increase in the duration of 
sleep when compared with the formulation at a dose of 250mg/kg.
Animals when forced to swim in a narrow space, from which it cannot 
escape, initially adopts a period of vigorous activity followed by an immobile posture, with 
movements necessary to keep their heads above water. The immobility posture was described as 
a sign of behavioral despair. Current studies have proved that, clinically active anti-depressants 
could greatly reduce the immobility time induced in the animal [113]. The formulation at doses 
250mg/kg and 500 mg/kg showed mild reduction in immobility time observed, when compared 
with the standard drug (Mephentramine 30mg/kg) which showed a significant reduction in the 
duration of immobility in mice.
EPM model is an etiologically convincing animal model of anxiety since it 
uses natural stimuli ie apprehension of new open space and fear of balancing on a comparatively 
lifted and slender platform (that could provoke anxiety in humans). The number of entries into 
the open arms and the time spent in open arms is increased by an anxiolytic agent [114]. The 
formulation at both doses did not affect the number of entries to both the arms. Standard drug 
diazepam at a dose of 5mg/kg increased the time spent and number of entries made by the animal 
in open arms. Formulation (low dose) showed moderate increase in the time spent in open arm as 
compared to the control group, whereas formulation (high dose) significantly increased the time 
spent by the animal in open arm as compared to the control group.
Hole board apparatus was considered as a promising animal model for 
evaluating the anxiolytic activity of drugs. The reduction in the number of nose poking was 
considered as an indicator of anxiolytic activity. The formulation at a concentration of 500mg/kg 
showed significant reduction in the number of nose poking made by the animal. The reduction in 
nose poking was comparable with that of the standard drug diazepam (5mg/kg). Formulation at a 
dose of 500mg/kg showed better anxiolytic activity when compared with the formulation at a 
dose of 250mg/kg.
The formulation at doses 250mg/kg and 500mg/kg and standard drug 
Diazepam 5mg/kg were used for evaluating the motor coordination in mice. The formulation at 
both the doses did not show any significant changes in the fall of time suggesting that the 
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formulation did not induce disturbances in motor coordination at the given doses, whereas the 
standard drug produced a significant reduction in fall off time. The results suggested that 
Kalyanakam kashayam did not show any signs of neurotoxicity.
The utmost intensity of stereotypy induced by Apomorphine was observed 
at 30 minutes. Stereotypy behaviour induced by Apomorphine was un-effected after the 
administration of the formulation at a dose of 250mg/kg. Whereas, the formulation at a dose of 
500mg/kg produced a mild drop in the stereotypic behaviour induced by Apomorphine. The 
results recommended that the formulation at a dose of 500mg/kg is an impending atypical 
antipsychotic against schizophrenia. 
The tranquillizer activity and the motor effects of drugs (those related to 
extra-pyramidal system) were evaluated by using this test. Conventional antipsychotic drugs well 
known for its foremost adverse effects like catalepsy, which forms a vital part concerned in the 
discovery and development of the antipsychotic drugs [115]. The Formulation at doses 250 and 
500 mg/kg were administered for evaluating the cataleptic behavior of the animals placed on a 
horizontal bar at two different heights 3cm and 5cm. The formulation at both the doses showed 
significant reduction in the cataleptic time when compared to the control group animals. The 
formulation at a dose of 500mg/kg was found to produce a significant reduction in the cataleptic 
score when compared with the score produced by the formulation at a lower dose (250mg/kg). 
The PTZ-induced seizures are comparable to the symptoms observed in 
the absence seizures (petit mal epilepsy), and drugs useful in the treatment of this type of 
epilepsy also suppress PTZ-induced seizures [116]. The antiepileptic activity of the formulation 
was evaluated in mice at two different doses, ie 250mg/kg (low dose) and 500 mg/kg (high 
dose), which was compared with that of the standard drug diazepam (4mg/kg). The standard drug 
produced promising anti-convulsant activity at the given dose, whereas the formulation showed 
better anti-convulsant activity at a dose of 500mg/kg when compared with the formulation at a 
dose of 250mg/kg. Formulation treated did not show any significant effect on the onset of 
convulsions. The animals treated with formulation and standard drugs were protected from death. 
                                                                                                                                       Conclusion
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10. CONCLUSION
The current study reveals that Kalyanakam Kashayam, an Ayurvedic 
polyherbal formulation possesses significant neuropsychopharmacological activity. The activities 
were evaluated using various animal models. 
The formulation showed significant in vitro anti-oxidant by ceasing the 
actions of free radicals. The formulation was studied for its anti-anxiety effect using elevated 
plus maze model and hole board test. Sleeping time assessment, forced swim test and 
spontaneous locomotor activity assessment were the models selected for evaluating the anti-
depressant activity. The other animal models used were rotarod test for evaluating neurotoxicity, 
apomorphine induced stereotypy, haloperidol induced catalepsy and PTZ induced convulsions in 
mice. 
The results suggested that the formulation Kalyanakam Kashayam 
produced significant potetiation of sleeping time induced by pentobarbitone; significant increase 
in locomotor activity; mild reduction in immobility time in forced swim test; significant increase 
in the time spent in open arm without effecting the number of entries to both the arms in elevated 
plus maze model, significant reduction in the number of nose poking in hole board test, 
significant reduction in cataleptic time induced by Haloperidol. The sample was found to be a 
better antipsychotic agent for the treatment of schizophrenia and is a non-neurotoxic drug. The 
anti-convulsant activity of the formulation was revealed in PTZ induced seizure models. 
Thus from the above reports it was concluded that the Ayurvedic 
formulation Kalyanakam Kashayam showed anti-oxidant activity and promising nootropic 
activity in Swiss Albino mice.
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